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NOTES
1. All the temperatures are expressed in degree centigrade (0C).
2. Melting points of all the compounds are uncorrected and have
been recorded by open capillary method.
3. Room temperature, wherever mentioned, normally corresponds
to 280 - 33 0C.
4. Silica gel-G was used for preparing the TLC plates using
different solvant systems.
5. Infra red spectra  of all the compounds were scanned on
SHIMADZU-FOURIER TRANSFORM INFRA RED (FTIR)-
8400 Spectrophotometer using KBr disc.
6. PMR Spectra were recorded on BRUKER Spectrophotometer
(300 MHz) using TMS as a internal standard and CDCI3, DMSO-d6
and TFA as solvants.
7. FAB mass spectra were recorded on JEOL SX 102/DA-600-
Mass Spectrometer. The matrix peaks may appear at m/z
136,137,154,289,307 in the absence of any metal ions
were not considered for mass fragmentations.
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A brief summary of the work to be incorporated in the thesis entitled
“STUDIES ON COMPOUNDS OF THERAPEUTIC INTEREST’’ has been
summarized as under.
    ( A ) STUDIES ON  PYRIMIDINES
    ( B ) STUDIES ON  PYRAZOLO[3,4-d]PYRIMIDINES
    ( C ) STUDIES ON  PYRIMIDO[4,5-d]PYRIMIDINES
    ( D ) STUDIES ON 1,4-DIHYDRO PYRIDINES
    ( A ) STUDIES ON  PYRIMIDINES
             Pyrimidines  represents one of the most active classes of compounds
possessing a wide range of biological activities viz. significant in vitro activity
against unrelated DNA and RNA viruses  including Polio and  Herpes  viruses,
diuretics, antitubercular, antihypertensive  etc. Some pyrimidines which
occur as natural products like nucleic acids  and vitamin-B  and can be used
as therapeutic agents for the treatment of AIDS and antitumor. Keeping in
association of pyrimidines with varied activities, it was thought worthwhile
synthesising some newer pyrimidines and its derivatives, which can be
summarized as under.
PART - I : STUDIES ON PYRIMIDINES
SECTION - I : Preparation and biological screening of 4-Amino-
2-mercapto-5-carbethoxy-6-(3’-aryl -1’ -N -phenyl-












Pyrimidines  (I) have been prepared by the cyclocondensation of 3-aryl-
1-N-phenyl-pyrazole-4-carboxaldehydes, thiourea and ethyl cyano acetate .










     ( II ) R=Aryl
Pyrimidines  (II) have been prepared by the cyclocondensation of 3-aryl-
1-N-phenyl-pyrazole-4-carboxaldehydes , urea and ethyl cyano acetate .










   ( III ) R=Aryl
Pyrimidines  (III) have been prepared by the cyclocondensation of 3-aryl-
1-N-phenyl-pyrazole-4-carboxaldehydes, guanidine hydrochloride  and
ethyl cyano acetate.













                                                              ( IV ) R=Aryl
Pyrimidines (IV) have been prepared by the reaction of 4-amino-2-
mercapto-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro
pyrimidines  with dimethyl sulphate  in presence of the  base.












  ( V ) R=Aryl
Pyrimidines (V) have been prepared by the reaction of 4-amino-2-
methylthio-5-carbethoxy-6-(3’-aryl-1’-phenyl-pyrazol-4’-yl)-1,6-dihydro
pyrimidines  with hydrogen peroxide .















   ( VI ) R=Aryl
Pyrimidines  (IV) have been synthesized by the condensation of 4-amino-
5-carbethoxy-2-mercapto-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro
pyrimidines  with 2,4-dinitro chloro benzene  in the presence of base.














  ( VII ) R=Aryl
Pyrimidines (VII) have been prepared by the reaction of 4-amino-5-
carbethoxy-2-[(2",4"-dinitrophenyl)thio]-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl) -
1,6-dihydro pyrimidines with hydrogen peroxide .
( B ) STUDIES ON PYRAZOLO[3,4-d]PYRIMIDINES
Pyrazolo[3,4-d]pyrimidines  are one of the most active classes of
compounds possessing diverse biological activity viz. anticancer, antitumor,
diuretic, antipyretic  and antimicrobial. Prompted by above facts some new




PART-II : STUDIES ON  PYRAZOLO[3,4-d]PYRIMIDINES









( VIII ) R=Aryl
Pyrazolo[3,4-d]pyrimidines  (VIII)  have been prepared by the
cyclocondensation of 3-amino-1-N-phenyl-5-pyrazolone, thiourea and
aromatic aldehydes.









( IX ) R=Aryl
Pyrazolo[3,4-d]pyrimidines  ( IX) have been prepared by the
cyclocondensation of 3-amino-1-N-phenyl-5-pyrazolone , urea and  aromatic
aldehydes.












( X ) R=Aryl
Pyrazolo[3,4-d]pyrimidines ( X ) have been prepared by the cyclocondensation
of 3-amino-1-N-phenyl-5-pyrazolone, guanidine hydrochloride and aromatic
aldehydes.










( XI ) R=Aryl
Pyrazolo[3,4-d]pyrimidines (XI) have been prepared  by the reaction of
3-Amino-4-aryl-6-mercapto-1-N-phenyl-4,5-dihydro pyrazolo[3,4-d] pyrimidines
with dimethyl sulphate  in presence of base.
















Pyrazolo[3,4-d]pyrimidines  (XII) have been prepared by the reaction of
3-Amino-4-aryl-6-methylthio-1-N-phenyl-4,5-dihydro pyrazolo[3,4-d]-
pyrimidines  with hydrogen peroxide .











( XIII ) R=Aryl
Pyrazolo[3,4-d]pyrimidines (XIII) have been prepared by the reaction
of 3-amino-4-aryl-6-mercapto-1-N-phenyl-4,5-dihydro pyrazolo[3,4-d]-
pyrimidines with 2,4-dinitro chloro benzene  in the presence of base.













( XIV ) R=Aryl
Pyrazolo[3,4-d]pyrimidines (XIV) have been prepared by the reaction
of 3-Amino-4-aryl-6-[(2’,4’-dinitrophenyl)thio]-1-N-phenyl-4,5-dihydro-




   ( C ) STUDIES ON  PYRIMIDO[4,5-d]PYRIMIDINES
              Pyrimido[4,5-d]pyrimidines  have been found to be potent drugs in
pharmaceuticals and possessing a wide spectrum of biological activities like
anticancer, antitubercular , antihypertensive, antitumor and antibacterial.
In view of procuring highly biodynamic agents and after reviewing literature
survey on pyrimido[4,5-d]pyrimidines for their various methods of synthesis
and different biological activit ies encouraged us to prepare some novel
pyrimido[4,5-d]pyrimidines with better potency, which have been described
as under.
PART - III : STUDIES ON PYRIMIDO[4,5-d]PYRIMIDINES












( XV ) R= Aryl
Pyrido[4,5-d]pyrimidines (XV) have been synthesized by the
condensation of 2-mercapto-4–amino-5-carboxamido-6-(4’-nitro phenyl)-
pyrimidine and  aromatic aldehydes.

















Pyrido[4,5-d]pyrimidines  (XVI)  have been synthesized by the
condensation of  2-mercapto-4-amino-5-carboxamido-6-(4’-nitro phenyl)-
pyrimidine with aromatic acetophenones.
( D ) STUDIES ON 1,4-DIHYDRO PYRIDINES
1,4-Dihydro pyridines possess antihypertensive, cardiovascular,
vasodilator, antitubercular and antimicrobial activi t ies.  These valid
observations lead us to synthesize some novel 1,4-dihydro pyridines  that have
been described as under.
PART - IV : STUDIES ON 1,4-DIHYDRO PYRIDINES








                                                    ( XVII ) R= Aryl
             1,4-Dihydro pyridines (XVII) have been prepared by the cyclo condensation
of 3-(4’-methoxyphenyl)-1-N-phenyl-pyrazole-4-carboxaldehyde , ethyl
acetoacetate and  aromatic amines .








H 3COOC COOCH 3
R
OCH 3
( XVIII ) R= Aryl
1,4-Dihydro pyridines (r) have been prepared by the cyclocondensation
of 3-(4’-methoxyphenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde , methyl
aceto acetate  and aromatic amines .
SECTION - III : Preparation and  biological evaluation of 1-N-Aryl-2,6-
diethyl-3,5-dicarbethoxy-4-(1’-N-phenyl-3’-(4"-nitro
phenyl)- pyrazol-4’-yl)-1, 4-dihydro pyridines.
N N
N CH 3CH3
H 5C 2OOC COOC 2H 5
R
NO 2
  ( XIX ) R= Aryl
1,4-Dihydro pyridines (XIX) have been prepared by the cyclocon-
densation of 3-(4’-nitro phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde , ethyl
aceto acetate and aromatic amines .








H3 COOC COOCH 3
R
NO 2
  ( XX ) R= Aryl
1,4-Dihydro pyridines (XX) have been prepared by the cycloconden-
sation of 3-(4’-nitro phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde , methyl-
aceto acetate  and aromatic amines .
The purified synthetic compounds have been screened for their in vitro
therapeutic assay like antibacterial activities  towards S. pyogens MTCC-442
and S. aureus  MTCC-96  (Gram positive)  and E.coli MTCC-443 and B.subtilis
MTCC-441  (Gram negative)  bacterial strain and antifungal activity  towards
Aspergillus niger   MTCC-282 and Candida albicans MTCC-227 at different
concentrations (Minimum Inhibitory  Concentration). The biological activities
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STUDIES ON COMPOUNDS OF THERAPEUTIC INTEREST
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb’. It is the single active chemical entity present in a medicine that is
used for diagnosis, prevention, treatment / cure of a disease. This disease
oriented definition of drug does not include contraceptives or use of drugs for
improvement of health. According to “WHO” a drug may be defined as “Any
substance or product which is used or intended to be used for modifying or
exploring physiological system as pathological status for the benefit of the
recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with living
system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the over effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have been
purified, chemically characterized and a vast variety of highly potent and
select ive new drugs has been developed. The two main div is ions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics :  It is derived from the Greek word “dynamic” means
power. What the drugs does to the body ? This includes physiological and bio-
chemical effects of drugs and their mechanism of action at macro molecu-
lar / sub cellular organ systems.
(b) Pharmacokinetics :  It is derived from the Greek word ‘Kinesis’ means
G e n e r a l  I n t r o d u c t i o n
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movement. What the body does to the drug ? This refers to movements of
the drug in and alternation of the drug by the body; includes absorption,
distr ibut ion, binding /  local izat ion /  storage, biotransformation and
excretion of the drug.
Some other important aspects of pharmacology are given as under :
* P h a r m a c o t h e r a p e u t i c s  :  I t  i s  t h e  a p p l i c a t i o n  o f  p h a r m a c o -
dynamic  information together with knowledge of the disease for its
prevention, mitigation or cure.
* Clinical  Pharmacology  :  I t  is  the scient i f ic  study of  drug in man.
It  inc ludes pharmacodynamic and pharmacokinet ic  invest igat ion
i n healthy volunteers and in patients; evaluation of efficiency and safety
o f  d rugs  and  compara t i ve  t r ia l s  w i th  o ther  fo rms o f  t rea tments ;
surveillance of patterns of drug uses, adverse effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
wi th  spec i f i c  d rugs  tha t  have se lec t ive  tox ic i ty  fo r  the  in fec t ing
organism / malignant cell with less effect on the host cells.
Drugs in general, can thus be divided into :
* Pharmacodynamic agents : These are chemical substances designed
to have pharmacodynamic effect in the recipient.
* Chemotherapeut ic  agents :  These are chemical substances de-
signed for the treatment of infectious diseases or by the proliferation of
malignant cells.
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs as
“those that satisfy the healthcare needs of majority of the population; they should
therefore be available at all times in adequate amounts and in appropriate
dosage form”.
It has been realized that only a handful of drugs out of the multitude
G e n e r a l  I n t r o d u c t i o n
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available can meet the health needs of majority of the people in any country, and
that may be well tested and cheaper drugs are equally (or more) efficient and
safe as their newer more expensive congeners. For optimum utilization of
resources, governments (specially in developing countries) should concentrate
on these drugs by identifying them as Essential Drugs. The “WHO” has laid down
criteria guide selection of an essential drug :
(I) Adequate data on its efficiency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability,
and stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; availability
o f  fac i l i t ies  and t ra ined personnel ;  f inanc ia l  resources;  genet ic ,
demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the basis
          of their relative efficiency, safety, quality, price, availability and cost
          benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic properties
and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combination
products should be included only when dosage of each ingredient meets
the requirements of a defined population group, and when the combination
has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations and
progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practise for combating
human ailments existent during early human observation. With the advent of
modern scientific approach, various plant medicines came under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
G e n e r a l  I n t r o d u c t i o n
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Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
for over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemical
investigations followed by pharmacological evaluation led this compound into the
modern medicine. Similarly during this period, urea stibamine was introduced as
the first drug in 1920 for the treatment of Kala-azar. In 1930, De Rauwolfia
preparation were first employed for sedative and hypotensive properties.
A drug is a substance having abnormal effect on certain body functions eg.
Strychnine stimulates the action of heart and aspirin retards its action. Since both
of them effects abnormally, the two substances are known as drugs. Chemical
sciences contributed extensively new discoveries leading to useful drugs since
after 1930. The modern concept of drug discovery started in 1933 by Gerhand
Domagk with his finding of “Prontosil Red”, a compound responsible for the
antibacterial activity. The advent of sulphonamides drew the attention for the
different activities of various chemicals for bacterial and human cells, this
important factor prompted Florey and Chain in 1939 to investigate penicillin
which was discovered ten years earlier by Alexander Fleming. The spec-
tacular chemotherapeutical properties of penicillin  and its dramatic war-time de-
velopment for the treatment of wounds made penicillin , a most commonly used
inexpensive drug.
           A large number of important drugs have been introduced during the period
of 1940 to 1980. This period is known as “Golden period” of new drug discovery.
Thus starting from 1933 - the first antibacterial drug prontosil  leading to various
sulpha drugs ; 1940 – penicillin  ; 1945 – chloroquine – antimalarial ; 1950 –
Methyldopa  – anti-hypertensive; 1967 – chlorothiazine  -diuretic; 1958 - adren-
ergic beta blockers coronary vasodilatory; 1960 - semi synthetic penicillin  -
antibacterial;1965-trimethoprim-antimicrobial;1967-  disodium chromoglycoate
- antiallergic; 1972 - cimetidine H2 – antagonist; 1975 -verapamil  - calcium an-
tagonist and 1981 - captopril - antihypertensive. There are some specific examples
representing new therapeuticagent eg. Metormine glipizide -anti diabetic.
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(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and the
drug discovery community. In numerous laboratories the Efforts are focused on
the introduction of chemical diversity, which have been recently reviewed and
pharmacologically interesting compounds have been identified from libraries of
widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, together
with so-called organometallics. Such agents have their origin in a number of ways
(a) from naturally occurring materials - of both plant and animal origin, and (b)
from the isolation of organic compounds synthesized in laboratory whose struc-
tures are closely related to those of naturally occurring compounds for eg. atropine,
steroids, morphine, cocaine etc. that have been known to possess useful medicinal
properties.
The process of drug design is extensively driven by the instinct  and expe-
rience of pharmaceutical research scientists. It is often instructive to attempt to
“capture” these experiences by analyzing the historical record that are successful
drug design projects of the past. From this analysis, the inferences are drawn
which play an important role in shaping our  current and future projects. Towards
this region, we would like to analyse the structures of a large number of drugs -
the ultimate product of a successful drug design effort. Our goal for this is to  begin
to deconvolute this information in order to apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases viz.
which can be defined with their names of the modern drugs are as under.
(a) Anticancer drugs
The drugs, which stops the abnormal growth of cell tissues in human body,
are termed as anticancer drug. Vinblastin and Busulphan are the novel
anticancer drugs.




Drugs, which gives vitality to liver and protects liver by giving immunity power
against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antimalarial
drug. Combination of Sulphamethoxazole with Pyrimethamine is a novel
antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs Cifalexin  is a novel meningitis drug.
(e)      Drug for typhoid
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin .
(f)       Antidiabetic drugs
Drugs, which converts the excess glucose of blood into glycogen are termed
as antidiabetic drugs. Novel antidiabetic drugs are Metformin, Glipizide and
Gliclazide .
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus cures
lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respiration
are called antiasthamatic drugs. Novel antiasthamatic drugs are Ethophylline,
Theophylline and Asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels are
called antihypertensive drugs. Novel antihypertensive drugs are Atenolol,
G e n e r a l  I n t r o d u c t i o n
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Amlodipine and  Nifedipine.
(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine .
(k) Antacid drugs
           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are Omeprazole
and  Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation are called
NSAID. Novel NSAID are Pyroxicam, Meloxicam and  Nimesulide.
Different kind of drugs generally used are designed as anaesthetic,
anti tuberculostat ic, antihypertensive, anticonvulsant, anthelmintic,
antiinflammatory, sedative and hypnotics which prompted us to synthesise drugs
having pyrimidine, quinoline, pyrazolo[3,4-d]pyrimidine, pyrido[2,3-d : 6,5-d’]-
dipyrimidine moieties as a better therapeutic activity.
Aims and objectives of the present investigation are,
(a) To generate several biologically active moieties such as pyrimidines,
pyrazolo[3,4-d]  pyrimidines, pyrido[2,3-d : 6,5-d’]dipyrimidines and 1,4-dihydro
pyridines.
(b) To characterize these products for their structural assignment using various
             spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using different
strains of bacteria and fungi and to compare antimicrobial activity with
G e n e r a l  I n t r o d u c t i o n
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In view of these facts, the research work presented in thesis are as
follows.
    ( A ) STUDIES ON  PYRIMIDINES
    ( B ) STUDIES ON PYRAZOLO[3,4-d]PYRIMIDINES
    ( C ) STUDIES ON  PYRIMIDO[4,5-d]PYRIMIDINES
    ( D ) STUDIES ON 1,4-DIHYDRO PYRIDINES
P A R T - I
S T U D I E S  O N



































































Pyrimidine  (1) is a six membered heterocyclic compound consisting of
two nitrogen atoms at 1 and 3 positions of heterocyclic ring.
Generally pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidine,
2-mercapto-substituted-pyrimidine  and 2-amino-substituted-pyrimidine  are
studied. Pyrimidines  have been isolated from the nucleic acid hydrolysates.
Pyrimidines  are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogues of
pyrimidines  have been used as compounds that interfere with the synthesis and
functioning of nucleic acids e.g. fluorouracil, which has been used in cancer
treatment. Also there are some thiouracil  derivatives, which produce adverse
reduction in susceptible patients and found more potent and less likely to
produce side effects and is being widely used1. There are several other
important groups of pyrimidines  with medicinal uses.
Pyrimidine  ring carrying various substituents may be built up from two or
three aliphatic fragments by the principle synthesis or by a variety of other
syntheses, which are complimentary rather than alternative to it. An alternative
method of synthesis is the isomerisation or break down of another heterocycles
such as hydration of purine , but such methods are rarely used. Pyrimidine  is
best  considered as a resonance hybrid to which the uncharged equivalent Kekule
N
N
   pyrimidine
(1)
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structures 2 and 2a and charged structures 2b and 2g contributes. The self con-
sistent p (pi) electron densities required for the ground state of pyrimidine are
0.776, 0.825 and 1.103 for positions 2, 4  and 5 respectively2. Despite considerable
localization of p (pi) electrons at nitrogen atoms of pyrimidines  the ring system
is still sufficiently aromatic to possess substantial stability. This has a great
advantage in the primary synthesis of pyrimidines .
The first primary synthesis from aliphatic fragments was carried out by
Frankland et al. in 1848. Since then a many distinct primary synthetic methods
have been devised3-12.  It is also possible to prepare pyrimidines  from other
heterocyclic compounds such as pyrrole13 , imidazole14 , isoxazole and
oxazole15,16, pyridine 17, pyrazine 18, 1,3,5-triazine19, oxazine20, thiazine 21 by
different processes.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines   which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of pyrimidine22.
(b) By the condensation of malonic ester and urea led to formation of pyrimidine23.
(c) By the condensation of formamidine with phenylazomalononitrile led
to formation of 4,5,6-triamino pyrimidine24.
(d) By the condensation of aromatic aldehydes, ß-ketoester  or substituted
ß- ketoester with urea or thiourea led to formation of pyrimidines25.
(e) By the condensation of thiourea  and substituted ß-ketoester  in presence
of sodium ethoxide  led to formation of 2-mercapto pyrimidines26
(f) By the condensation of chalcones with dicyandiamide  in presence of
piperidine led to formation of pyrimidines27.
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in presence of dimethylformamide  led to formation of substituted tetra
hydro pyrimidines.28
(h) One pot synthesis of substituted dihydropyrimidin-2-ones catalysed
by CuCl2.
29
(i) Synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones  under microwave
irradiation.30
(j) One pot efficient and novel synthesis of dihydropyrimidin-2-(1H)-ones
catalysed by Tin (II) chloride (SnCl2)
.31
(k) By microwave induced eco-friendly solvent free Biginelli reaction catalysed
by calcium chloride.32
Pyrimidines have found their applications as herbicidal33and pesti-
cidal34,35  agents. Yoshida et al.,36 have synthesized 4-amino-5-formyl-2-
mercapto pyrimidines  as agrochemical intermediates.  Srivastava C. et al.,37
have synthesized new substituted pyrimidines  (3) as  potential insecticides. N.
Yasushi et al.,38  synthesized 6-(1-fluoro ethyl)-5-iodo-4-alkylamino pyrimidines
(4) as pesticides for agriculture and horticulture. Besides such a great biological
importance of pyrimidines , they also contribute to an important class of dye viz.
trichloro pyrimidine39  dye which is a reactive dye. Pyrimidines also have
applications in liquid crystal composition.40 Many synthetic members of pyrimidines
are important as vulcanizing accelerator agents and  photography stabilizer. 41
PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES
Numerous pyrimidines  are well  known drugs for vari
ety of diseases. They may be placed in four categories viz. barbiturates, sulfona-
















R = Alkyl/Aryl (4)
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chroticacid, willardiline, tetradotoxine, becimethrian (5), blasticidine (6),
cougerotin, amicetin, bamicetin  and plicacetin, phleomicine, blemycin  and
related families (7).
Pyrimidine  derivatives have wide varieties of usages. Pyrimidine  ring
system is also present in Vitamin B2 and folic acid. Pyrimidine  ring system
having a mercapto group occupy a unique position in medicinal chemistry. 42
These types of derivatives play a vital role in biological processes43-45 as well
as synthetic drugs.46
Some of the therapeutic activit ies of pyrimidine derivatives can be
summarized as follows.
(a) Antithyroid47,48 (b)      Antitumor49-51
(c)      Antihypertensive 52-54               (d)      Antiinflammatory55-57
(e)      Diuretic58 (f)       Antimalarial59-61
(g)      Antispasmodic62 (h)      Anticonvulsant63
(i)       Antineoplastic64,65 (j)       Anthelmintic66
(k)      Antimicrobial67-92 (l)       Cardiovascular93-95
(m)     Antiviral96-99 (n)      Platelet aggregation inhibitor100,101
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The basis of any rational drug discovery programme is fundamently, the
Medicinal Chemistry. Although the synthesis of modified nucleic acids  has been
a subject of interest for some time, the intense focus on the medicinal chemistry
of oligonucleotides dates perhaps to not more than five years. As a result of this,
the scope of medicinal chemistry has recently been expanded enormously, but
the biological data of supporting the conclusions about synthetic strategies have
just begun to emerge.
Modi f icat ions in the base,  sugar and phosphate moei t ies of
oligonucleotides and oligonucleotide conjugates have been reported. The
subjects of medicinal chemical programmes include approaches to create
enhanced affinity and more selective  affinity for RNA  or duplex structures, the
ability to cleave nucleic acid targets, enhanced nuclease stability, cellular
uptake and distribution, in vivo  tissue distribution, metabolism and clearance.
Although substantial progress in the medicinal chemistry of oligonucleotides has
been made in the past three years, it is not yet possible to reach the conclusion
about the therapeutic ability of the novel modifications. Preliminary data on
effects on nuclease stability and hybridization properties for a few modifications
and activity in vitro suggest that the next generation of oligonucleotides may
display substantially improved potencies and selectivity.
PYRIMIDINE MODIFICATIONS (Nucleotide)
A relatively large number of modified pyrimidines  have been synthesized
and now incorporated into oligonucleotides and evaluated. The principle sites of
modification are   C-2, C-4, C-5 and C-6. (8). These and other nucleoside














Sites of pyrimidine Modification
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In as much as the C2 position is involved in Watson-Crick hybridization,
oligonucleotides containing C2 alkyl modified pyrimidines have shown unattractive
hybridization characters. However, an oligonucleotide containing 2-thio
thymidine(9) was found to hybridize well to DNA  and, in fact even better to RNA
with a thermal melting temperature ( DTm) value of 1.5 °C/modification. In a differ-
ent study, oligoribonucleotides with 2’-O-methyl-2-thiouridine(10) exhibited a
thermal melting temperature ( DTm) value of +5.5°C/modification when hybridized
against RNA  resulting from a highlly preoganized RNA -like C3’-endo conforma-
tion (attributed to the combination of 2-thio modification and 2’-O-Me substitu-
ent). Oligonucleotides with this modification also exhibit better hybridization dis-
crimination for the wobble uracil-guanosine  (U-G) base pair formation compared
to the normal uracil-adenine (U-A) base pair. This selectivity is a result of weaker
hydrogen bonding and increased steric bulk of the 2-thiocarbonyl group.108
In contrast, the pyrimidine modifications in 4-position with interesting
properties have been reported. 4-Thiopyrimidines(11,12) have been incorporated
into oligonucleotides with no significant negative effect on hybridization.However,
recent studies have shown destabilization in the normal uracil-adenine  (U-A)
base pair formation and stabilization of the wobble uracil-guanosine (U-G)  base
pair for 4-thiouridine . A bicyclic and an 4-methoxy  analog of cytosine were
shown to hybridize with both purine bases in DNA with thermal melting temperature
(Tm) values approximately equal to that of natural base pairs.  Additionally, a
fluorescent base has been incorporated into oligonucleotides and shown to en-
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The pyrimidine modification at C 5 position including halogenated nucleo-
sides have been reported. Although the stability of duplexes may be enhanced by
incorporation 5-halogenated uracil containing nucleosides, the occasional
mispairing with guanidine and the potential that the oligonucleotide might
degrade and release toxic nucleosides analogs cause concern. Oligonucleotides
containing 5-propynylpyrimidine(14,15) modification have been shown to
enhance the duplex stability thermal melting temperature (DTm = 1.6°C/modifi-
cation ), and support RNase H activity. The 5-heteroaryl-pyrimidines  were also
shown to  increase the stability of duplexes . A more dramatic influence was
reported for the tricyclic 2’-deoxycytidine analoges, termed phenoxazine,
exhibiting an enhancement of 2-5°C/modification, depending on the positioning of
the modified bases.110
As expected, modifications in the C6 position of pyrimidines  are highly
dupled destabilizing. Oligonucleotides containing 6-azapyrimidines(16) have
been shown not only to reduce the  thermal melting temperature (Tm) value by
1-2°C per modification, but also to enhance the nuclease stability of oligonucle-
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PYRIMIDINE MODIFICATIONS (Non-nucleotide)
The increasing interest in the early 1970s in properties and use of interferon
(IFN) together with the difficulty in producing useful amounts of interferon (IFN)
led to the search for agents that would induce IFN in the host. Precedenced at
that time for interferon (IFN) inducers included viruses and bacterial wall constituents
and entities of large molecular weight such as the polynucleotides. There were
also several examples of low molecular weight substances such as certain antibiotics
and the antiviral agent, tilorone.112-113 In 1976 it was reported that 6-methyl
pyrimidinone (2-amino-5-bromo-6-methyl-4-(3H)pyrimidinone, ABMP) induced
circulating levels of interferon (IFN) in several animal specis upon oral or intraperitoneal
administration.114 Subsequent structure-activity studies yielded a more potent and
less toxic 6-phenyl ananlog called ABPP or bropirimine (2-amino-5-bromo-6-phenyl-
4-(3H)pyrimidinone) (figure 1 and Table 1).115,116 Bropirimine and related  6-aryl
analogs were examined extensively for efficacy in virus and tumor models, along













     Figure 1 :  Preliminary SAR of antiviral activity of pyrimidinones
                                     
(underlined substituents were active)
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         Antiviral  activity
monosubstituted Disubstituted Heterocyclic
Active         2-F,OMe, Me 3,5-OMe 1-Naphthyl
          3-F,OMe, Cl, NO2 2,5-Cl2 2-Pyrazyl
Me, CF3, MeCH2CH2O, 3,5-OMe 2,3-pyridyl
Br,I 3,4-Cl2 2-Furyl
4-F, Cl 3,5-Cl2
Inactive 4-Me, CN, Butyl, 2,3-OMe 2-Napthyl
OH,OCH2ph, OMe 1-Furyl
4-Pyridyl
                                         2-Quinoline
As with the polynucleotides, the pyrimidinones  exhibited significant       ac-
tivity against interferon (IFN) sensitive viruses such as Semliki Forest virus in vivo.
However, in addition, they exhibited prophylactic and therapeutic activity upon
either local or systemic administration to rodents infected with a variety of DNA
viruses, such as the herpes viruses (HSV-1, HSV-2 , CMV  and pseudorabies) ,
and when administered intranasally for upper respiratory infections, such as
infectious bovine rhinortacheites, influenza A and para-influenza-3. Particularly
interestion activity was noted  with bropirimine on intravaginal administration in
protection against HSV-2 intravaginal infection in guinea pigs, an important model
for genital herpes in humans.118 Bropirimine  also exhibited activity when given
either intraperitoneally or orally to mice infected with Listera monocytogenes. The
efficacy in this model  was not abrogated by the addition of anti-interferon (IFN)
antibody. 119
Pyrimidines as Antifolates
        During a preliminary clinical trial designed to establish safety and suitability
for use in the treatment of cancer, Farber found the folic acid derivatives
pteroyldiglutamic acid (17) and pteroyltriglutamic acid  (18) were accelerating
the growth of malignant cells in the bone marrow of patients with acute leukaemia.
He obtained the newly synthesized antifolate pteroylaspartic acid from Subba Row,
from which encouraging results were obtained in children with acute leukaemia.
Better responses were observed with the aminopterin (19) and methotrexate(20).
Injections of methotrexate induced temporary remissions in 30% of children, but
Table - I
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Farber and his colleagues later combined it with drugs such as cortisone
and mercaptopurine to achieve results which paved the way towards the
currentposition where most children can be cured of the disease if given the ap-
propriate treatment. The precise model of action of the antifolates became ap-
parent in 1952. This was the inhibition of dihydrofolate reductase , the enzymes
that catalysed the transformation of folic acid so that it could be utilized for the
synthesis of thymine  for incorporation into  DNA. Surprisingly, no other antifolate
















(17)   n = 0, R = NHCH(COOH)CH2CH2COOH
(18)   n =2,  R = OH
(19)    R = H











5-Azacytidine ( Azacitidine; 21)  the most active of the azapyrimidines ,
shows substantial activity in the treatment of murine and human leukaemas, but
little useful activity against solid tumours.120  It is phosphorylated in vivo  to the
mono-,di- and tri- phosphate levels, and inhibits nucleic acid synthesis and function.
In calf thymus nuclei, the synthesis of mRNA is inhibited, while the incorporation
of 5-azacytidine  into tRNA decreases amino acid acceptor activity for most of
the amino acids , further suppressing protein synthesis.121
5-Azauracil  (22) and 5-azaorotic acid (23) are competitive inhibitors of
orotate phosphoribosyltransferase122  and show activity against adenocarci-
noma 755, but not against LI210 leukaemia.
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6-Azauridine (24) was formerly used to treat chronic myelogenous and
acute leukaemias123 , as well as psoriasis and mycosal infection. For the latter
conditions, it was applied as its prodrug 2’,3’,5’-tri-O-acetyl-6-azauridine
( Azaribine; 25) which has been withdrawn from the market. 6-Azauridine  is phos-
phorylated in vivo to it’s 5’-monophosphate, which inhibits orotidylic acid
metabolism, is primarily responsible for it’s cytotoxic effects.
Of the various halogenated pyrimidines which have been prepared, only
the fluorinated pyrimidines and nucleosides have useful antitumour activity, and
of these the most significant are 5-fluorouracil (FU) and it’s 2’-deoxyribo-
nucleside (FUdR; Floxuridine). Both of these drugs have found wide uses in
patients suffering from metastatic cancer, and have been administered both sin-
gly and in combination therapy.
The presence of flourine, which cannot be abstracted by base, halts the
process. In contrast, the 5’-monophosphate  of 5- chloro-, 5- bromo- and 5-iodo-
2’-deoxyuridine, in which the halogen atom is bulkier and less electronegative,
have little or no useful inhibitory activity for the enzyme. The drugs of fluorouracil
(FU) showing good antitumour activity includes it’s 1-t-butylcarbamoyl124,1-
hexylcarbamoyl125 and 1-methoxycarbonylmethylcarbamoyl126derivatives,
5’-deoxy-5-fluorouridine127 and methyl-1-(5-fluoro-1-H-2-oxopyrimidin -4-yl)-
B-D-glucopyranuronate  (26).128 All of these contain in essence the fluorou-
racil (FU)  moiety, ready via oxidative or hydrolytic means. 5-Fluoropyrimidin-4(1H)-
one, with activity against tumours in experimental animals, is a different type of























     (21)                    (22) R = H        (24)     R = H
(23) R = COOH         (25)     R = MeCO
Antagonist  : A chemical substance that interferes with the physiological action of another, especially by
         combining with and blocking its nerve receptor.
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A number of prodrugs of FUdR have also been prepared a notably potent
member being 5-bromo-6-methoxydihydro-5-fluro-2’-deoxyuridine  (27).130
finally, a different species of fluoro-pyrimidine  derivative, which as its 5’-mono-
phosphate  inhibits thymixylate synthetase is 5-trifluoromethyl-2’-deoxyuridine
( Trifluridine ; 28)  it possesses a higher therapeutic index against adenocarci-
noma 755 in mice than 2’-deoxyribo-nucleoside (FUdR; Floxuridine) .131

























PYRIMIDINES AS ANTITUMOUR AGENTS
A number of other pyrimidine antagonists displaying antitumour activity, in
which the base is conjugated to a modified suger ring have been reported.
Although D-Arabinofuranosyl uridine (ara-uridine)  shows no useful acitivity,
and 5-bromo-and 5-iodo-D-arabinofuranosyl uridine inhibit the growth of  sarcoma
180 and L1210 cells in culture.132 Other thymidine analogues with similar activity
inc lude  5 -az idomethy l - , 5 -aminomethy l and  5 -hydroxymethy l -2 ’ -
deoxyuridine 133.  3’-Amino-3’-deoxy thymidine134  and 3’-amino-2’,3’-
dideoxycytidine135  also posses strong activity against L1210 leukaemia 2’-
Deoxy-2’-fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU; 29)  is highly
active against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815 cell lines
both in vitro and in vivo.136  2-B-D-Ribofuranosylthiazole-4-carboxamide
(Tiazofurin; 30) has aroused much interest recently for its activity against solid
tumour such as lung carcinoma. It is metabolized to an analogue of NAD  in which
the thiazole-4-carboxamide  moiety replaces the nicotinamide  ring. However, it
also depresses the synthesis of DNA  and RNA , and thus merits inclusion as an
antagonist of normal purine  and pyrimidine metabolism.137
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Targets for Antiviral Chemotherapy
Viral chemotherapy presents a quite different problem from tumour
chemotherapy. A virus 138  consists of a core of nuclear material, DNA  or RNA ,
containing specific viral genes, which may be associated with ‘core proteins’,
and which is surrounded by a protective proteincoat. The coat may have functional
protein appendages, and there may be present an ‘envelope’, rich in lipoprotein
and glycoprotein. The virus possesses no energy-producing or protein-synthesizing
machinery of its own. In order to reproduce, it must therefore become adsorbed
to a host cell, be transported across the cell membrane, and uncoat in order that
its viral genes may be expressed. The genome may require to be transported to
the cytoplasm or the nucleus. The nuclear material must then be replicated, and
the viral genes also transcribed into RNA  (assuming that we are dealing with a
DNA  virus) and  translated into virally specified protein. In addition to the coat
protein, viral enzymes will be produced in this process, and these are vital for
suborning the host cell’s internal biochemistry to serve the requirements of the
virus. Before the viral proteins can be made, a process of maturation of the viral
mRNA molecules, involving guanylylation and methylation to produce a ‘cap’ struc-
ture containing 7-methylguanosine 5’-phosphate in a 5’- 5’-pyrophosphate
structure at the 5’- end of the mRNA, must occur. Once the synthesis of the
components needed to make fresh viral particles has been completed, maturatian
occurs, in which the nucleic acid and protein components are assmbled to from
the complete viral particle or virion, and finally this is released from the cell as a
new , infective virus. RNA  viruses require that their nucleic acid be replicated
also, in order that new viral particles can form. Some RNA  viruses code for an
enzyme ‘transcriptase’ or ‘replicase’ (RNA -directed RNA polymerase), which
replicates RNA  strands directly without involving DNA139  while others encode
an enzyme ‘reverse transcriptase’ ( RNA  -directed DNA  polymerase), which tran-
scribes the RNA  sequence into DNA -the reverse of the usual sequence which
can subsequently become integrated into the host cell chromosome and is tran-
scribed to from copies of the viral RNA.140  Purine and pyrimidine antimetabolites
which are active against viruses are thus most likely to be effective by inhibiting
specifically the viral enzymes which are required to replicate the viral nucleic
acids, or inhibiting the viral enzymes responsible for transcription and capping of
mRNA,without  inhibiting the corresponding enzymes of the host cell.
Agonist : A drug which binds to a receptor and activates it, producing a pharmacological response.
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Alternatively, incorporation of an antimetabolite into a viral nucleic acid
causing the cessation of strand synthesis, or otherwise disturbing the normal function
of the nucleic acid in replication or in directing protein synthesis, offers another
way of preventing the replication of functional virus.141  Again, it is important that
the integrity of the nuclear material of the host cell should not be compromised.
One therefore seeks to exploit the differences between the viral enzymes to the
discomfiture of the virus.
5’- Amino-5-iodo-2’,5’-dideoxyuridine(Aminoidoxuridine; 32) displays good
antiherpes activity and is less cytotoxic than (31).142,143  The phosphorylation
of Aminoidoxuridine(32) is catalyzed specifically by virus-induced thymidine kinase,
and thus Aminoidoxuridine(32) is only potentiated in virus-infected cells. It inhibits
the synthesis of DNA  in infectedcells. The 5-bromo-, 5-chloro- and 5-trifluoro-
methyl derivatives of 5’-amino-2’,5’-dideoxyuridine also exhibit antiviral
activity144. 5-Iodo-2’-deoxcytidine (33) and 5-bromo-2’-deoxycytidine (34) also
show useful activity against herpes viruses and vaccinia with less cytotoxicity than
the uridine  compounds and more selective inhibition of virus replication.
PYRIMIDINES AS ANTI-HIV AGENTS
The strategy of designing nucleoside analogs that are selective for viral
DNA  polymerases is the most well-studied and successful approch to viral
chemotherapy, and has led to the discovery of several clinically useful antiviral
drugs. This strategy, however, has inherent limitations. Human DNA  polymerases
also required dNTP’s and the chemical mechanisms of polymerization by the viral
and human enzymes are similar. Nucleoside analogs often have significant host
toxicity that is probably related to inhibition of host cell DNA synthesis. Nevertheless,
         (29)                        (30)                    (31)  R= OH        (33)  X= I
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these compounds constitute the major class of antiviral drugs, and this approach
is likely to yield additional active compounds in the near future. For the long
term,however, other strategies may ultimately lead tonmmore selective agent withn
lower toxicity.
Obviously, the key to design analogue with a lower affinity for the host enzyme
than the viral enzyme, which requires that there be structural differences between
the enzyme active sites. For reverse transcriptase, the most well studied inhibitor
is 3’-azido-3’-deoxythymidine (AZT;  35), which is currently used clinically to treat
AIDS.145,146
3’-azido-3’-deoxythymidine (AZT)  inhibits HIV reverse transcriptase with
an IC50 of 40nM 147 , but is 100-300 times less active against mammalian DNA
polymerase a  and DNA  polymerase g . The reason for this selectivity is not clear
since 3’-azido-3’-deoxythymidine (AZT)  is a chain terminator for mammalian
DNA  polymerases and inhibits normal cellular DNA  synthesis.148 Several other
dideoxynucleoside analogs have been shown to be potent inhibitors of HIV
replication in vitro.149,150 In general, these compounds have the same mechanism
of action as 3’-azido-3’-deoxythymidine (AZT), that is, intracellular conversion
to the triposphate derivative and subsquent inhibition of HIV reverse transcriptase.
Some of these compounds are simply analogs of the nautral 2’-deoxy-
nucleoside in which the 3’-OH  group has been replaced with a hydrogen, such
as 2’,3’-dideoxycytidine(36), 2’,3’-dideoxyadenosine(37) and 2’,3’-dideoxy    thy-
midine(38). Other analogs contain a 2’-3’ double bond, such as  2’3’-didehydro-
2’,3’-dideoxythymidine  (39). Several related analogs with other modifications
to the ribose ring or the heterocyclic base moiety have also been reported to





































                       (36)              (37)                (38)             (39)
Recently, P. Khalili et al.153  have carried out biochemical and pharmaco-
kinetic evaluation of a novel nitric oxide  donor pyrimidine nucleoside hybrid
drug as a potential anticancer / antiviral agent. Rostom et al.154 have synthesized
and screened certain 2-(benzoxazol-2-yl-amino)-3H-4-oxopyrimidines for
in-vitro anti-HIV  activity.
A family of trisubstituted pyrimidines has been described as selective
COX-2 inhibitors. To explore the usefulness of pyrimidine derivatives as potential
NSAIDs. Aurelio Orjales et al155  have synthesized novel pyrimidine derivatives
40 and 41. In vitro biological evaluation of these compounds has provided     in-












40.  Y = CH; X,Z = N
41.  Y,Z = N; X = CH
In view of procuring highly potent biodynamic agents and after reviewing
recent literature survey on 2-hydroxy / mercapto / amino pyrimidines  for their
various methods of synthesis and different pharmacological activities, synthesis
of pyrimidines  have been undertaken which can be summarized in the following
sections as  follows:
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SECTION  - I : PREPARATION AND BIOLOGICAL SCREENING OF 4-
AMINO-2-MERCAPTO-5-CARBETHOXY-6-(3’-ARYL-1’-N-
PHENYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION  - II : PREPARATION AND BIOLOGICAL SCREENING OF 4-
AMINO-2-HYDROXY-5-CARBETHOXY-6-(3’-ARYL-1’-N-
PHENYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION  - III : PREPARATION AND BIOLOGICAL SCREENING OF 2,4-
DIAMINO-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-
PYRAZOL-4’-YL)-1,6-DIHYDRO  PYRIMIDINES.
SECTION  - IV : PREPARATION AND BIOLOGICAL SCREENING OF 4-
AMINO-2-METHYLTHIO-5-CARBETHOXY-6-(3’-ARYL-1’-N-
PHENYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION  - V : PREPARATION AND BIOLOGICAL SCREENING OF 4-
AMINO-2-METHYLSULPHONYL-5-CARBETHOXY-6-(3’-
ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-PYRIMIDINES.












PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
MERCAPTO-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-
1,6-DIHYDRO PYRIMIDINES.
Due to other properties107-155 and biodynamic activities 47-106 o f
pyrimidines and with a view to have potent therapeutic agents, the synthesis
of 4-amino-2-mercapto-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-
1,6-dihydro pyrimidines (Ia-h) have been undertaken by the condensation
of different 3-aryl-1-N-phenyl-pyrazol-4-carboxaldehydes with ethyl cyano
acetate and thiourea.
The constitution of the products (Ia-h ) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (Ia-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activit ies of the synthe-








(Ia-h)                 R=Aryl
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PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
MERCAPTO-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-
1,6-DIHYDRO PYRIMIDINES.
(A) Preparation of 4-amino-2-mercapto-5-carbethoxy-6-[3’-(p-methoxy
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (Ib) .
A mixture of 3-(p-methoxy phenyl)-1-N-phenyl-pyrazol-4-
carboxaldehyde  (2.78gm, 0.01 M), ethyl cyano acetate  (1.13 ml, 0.01 M) and
thiourea (0.76 gm, 0.01 M) in ethanol (30 ml) was heated under refluxed con-
dition for three hrs. Then the reaction mixture was kept at room temperature for
two hrs. The yellow crystalline product  so obtained  was isolated and recrystal-
lized from ethanol. Yield : 48%, M.P. : 216°C, R f1
 : 0.62, R f2
 : 0.65 (Required
:  C: 61.45%; H: 5.16%; N: 15.59% for C23H23N5O3S, Found : C: 61.40%; H:
5.12%; N:15.54% ).
Similarly, other compounds (Ia-h ) were synthesized. The physical data
are recorded in Table No. 1.
(B) Antimicrobial activity of 4-amino-2-mercapto-5-carbethoxy-6-(3’-
aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro pyrimidines(Ia-h ).
Antimicrobial  act ivi ty test ing was carr ied out by using cup-plate
method156 , which has been described as under.
     * Antibacterial activity
S. pyogens MTCC-442 and S. aureus MTCC-96 (Gram positive bacteria)
were grown in nutrient broth and E. coli MTCC-443 and B. subtillis MTCC-441
(Gram negative bacteria) in Peptone water (PW, 1% bacteriological peptone and
0.5% NaCl) for 24 hrs., this gave an optimum growth of the test  bacteria. Each
purified compound was dissolved in dimethyl formamide (DMF)  sterilized by
filtration by using sintered glass filter and stored at 4°C. Each agent was then added to
S t u d i e s  o n  P y r i m i d i n e s
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molten nutrient agar in the following concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 and poured into sterile petridished. The pH of the
media was maintained at 7.2 to7.4. The inoculum consisted of an overnight
grown broth culture of a bacterium diluted in such a manner that a 2 mm (internal
diameter) loopful of the culture contain 105 colony-forming unit (CFU). These
were then spot inoculated on nutrient  agar  plates containing increasing
amount of a compound, incubated at 37°C up to 24 hrs. for determination of
the minimum inhibitory concentration157,158  (MIC). Which are recorded in
zones of inhibition in mm for bacteria.
   * Antifungal activity
C. albicans MTCC-227 and A. niger MTCC-282 was employed for
testing antifungal activity using cup-plate method. The culture was maintained
on Sabouraud's agar for 72 hrs., this gave an optimum growth of the test fungal
spores. Each purified compound was dissolved in dimethyl formamide (DMF)
sterilized by filtration by using sintered glass filter and stored. Each agent was
then added to Sabouraud's agar in the following concentrations (µg/ml):  0
(control), 5, 10, 25, 50, 100, 200, 500  and poured into sterile petridished. The
inoculum consisted of an overnight grown broth culture of a bacterium diluted
in such a manner  than a 2 mm (internal diameter) loopful of the culture contain
105 colony-forming unit (CFU). These were then spot inoculated on Sabouraud's
agar plates containing increasing amount of a compound, incubated at 37°C up
to 48 hrs. for determination of the minimum inhibitory concentration
(MIC)157,158 . The MIC values of test solutions are recorded in Table No. 1a,
1b & 1c .  Which are recorded in zones of inhibition in mm for fungii.
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PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
HYDROXY- 5-CARBETHOXY-6-(3’ -ARYL-1’-N-PHENYL-PYRAZOL-4’-
YL)-1,6-DIHYDRO PYRIMIDINES.
Due to other properties107-155 and biodynamic activities47-106 of pyrimidines
and with a view to have potent therapeutic agents, the synthesis of 4-amino-
2-hydroxy-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro-
pyrimidines (IIa-h) have been undertaken by the condensation of different 3-
aryl-1-N-phenyl-pyrazol-4-carboxaldehydes with ethyl cyano acetate and
urea.
The constitution of the products (IIa-h) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IIa-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized








(IIa-h)                 R=Aryl
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PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
HYDROXY-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-1,6-
DIHYDRO PYRIMIDINES.
(A) Preparation of 4-amino-2-hydroxy-5-carbethoxy-6-[3’-(p-methoxy
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (IIb) .
A mixture of 3-(p-methoxy phenyl)-1-N-phenyl-pyrazol-4-
carboxaldehyde  (2.78gm, 0.01 M), ethyl cyano acetate (1.13 ml,0.01 M) and
urea (0.60 gm,0.01 M) in ethanol (30 ml) was heated under refluxed condition
for three hrs. Then the reaction mixture was kept at room temperature for two
hrs. The yellow crystalline product  so obtained  was isolated and recrystallized
from ethanol. Yield : 67%, M.P. : 201°C, R f1
 : 0.61, R f2
 : 0.71 (Required :  C:
63.73%; H: 5.35%; N: 16.17% for C23H23N5O4, Found : C: 63.68%; H: 5.29%;
N: 16.12% ).
Similarly, other compounds (IIa-h ) were synthesized. The physical data
are recorded in Table No. 2.
(B) Antimicrobial activity of 4-amino-2-hydroxy-5-carbethoxy-6-(3’-aryl-
1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro pyrimidines (IIa-h ).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 2a, 2b & 2c.
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PREPARATION AND BIOLOGICAL SCREENING OF 2,4-DIAMINO-5-
CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINES.
Due to other properties107-155 and biodynamic activities 47-106 of pyrimidines
and with a view to have potent therapeutic agents, the synthesis of 2,4-diamino-
5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro pyrimidines
(IIIa-h) have been undertaken by the condensation of different 3-aryl-1-N-
phenyl-pyrazol-4-carboxaldehydes  with ethyl cyano acetate  and guanidine
hydrochloride .
The constitution of the products (IIIa-h) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IIIa-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
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IR  SPECTRAL  STUDY  OF   2,4-DIAMINO-5-CARBETHOXY- 6 - [ 3’-(p-METHOXY
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PMR SPECTRAL STUDY OF  2,4-DIAMINO-5-CARBETHOXY-6-[3’-(p-METHOXY
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PREPARATION AND BIOLOGICAL SCREENING OF 2,4-DIAMINO-5-
CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-1,6-DIHYDRO-
PYRIMIDINES.
(A) Preparation of 2,4-diamino-5-carbethoxy-6-[3’-(p-methoxy phenyl)-
1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (IIIb) .
A mixture of 3-(p-methoxy phenyl)-1-N-phenyl-pyrazol-4-
carboxaldehyde  (2.78gm, 0.01 M), ethyl cyano acetate  (1.13 ml, 0.01 M) and
guanidine hydrochloride  (0.96 gm, 0.01 M) in ethanol (30 ml) was heated
under refluxed condition for three hrs. Then the reaction mixture was kept at
room temperature for two hrs. The yellow crystalline product so obtained  was
isolated and recrystallized from ethanol. Yield : 52%, M.P. : 118°C, R f1
 : 0.71,
Rf2
 : 0.81 (Required :  C: 63.88%; H: 5.59%; N: 19.44% for C23H24N6O3,
Found : C: 63.82%; H: 5.54%; N: 19.40% ).
Similarly, other compounds (IIIa-h ) were synthesized. The physical data
are recorded in Table No. 3.
(B) Antimicrobial activity of 2,4-diamino-5-carbethoxy-6-(3’-aryl-1’-N-
phenyl-pyrazol-4’-yl)-1,6-dihydro pyrimidines (IIIa-h ).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 3a, 3b & 3c.













































































































































































































































































































































































































   
   
   
   




   












   
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
METHYLTHIO-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-
1,6-DIHYDRO PYRIMIDINES.
Due to other properties107-155 and biodynamic activities 47-106 of pyrimidines
and with a view to have potent therapeutic agents, the synthesis of 4-amino-2-
methylthio-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro-
pyrimidines  (IVa-h) have been undertaken by the reaction of different 4-amino-
2-mercapto-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro
pyrimidines  with dimethyl sulphate  in the presence of base.
The constitution of the products (IVa-h) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IVa-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
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PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
METHYLTHIO-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-PYRAZOL-4’-YL)-
1,6-DIHYDRO PYRIMIDINES.
(A) Preparation of 4-amino-2-mercapto-5-carbethoxy-6-[3’-(p-methoxy
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (Ib) .
For preparation refer Part-I, Section-I, Page No. 43.
(B) Preparation of 4-amino-2-methylthio-5-carbethoxy-6-[3’-(p-methoxy
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (IVb).
A mixture of 4-amino-2-mercapto-5-carbethoxy-6-[3’-(p-methoxy phenyl)-
1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (4.49 gm, 0.01 M) and
dimethyl sulphate (1.26 ml, 0.01 M) in ethanol (30 ml) and 40% aqueous
sodium hydroxide  was stirred for 12 hrs. at room temperature. The content
was poured into ice cold water and filtered. The product was isolated and crystallized
from ethanol. Yield : 63%, M.P. : 223°C; Rf1
 : 0.67, Rf2
 : 0.62 (Required :  C,
62.18%; H, 5.44%; N, 15.12% for C24H25N5O3S, Found : C, 62.14%; H, 5.41%;
N, 15.06%).
Similarly, other compounds (IVa-h) were synthesized. The physical data
are recorded in Table No. 4.
(C) Antimicrobial activity of 4-amino-2-methylthio-5-carbethoxy-6-(3’-
aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro pyrimidines (IVa-h).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 4a, 4b & 4c.
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PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
METHYLSULPHONYL-5 -CARBETHOXY-6 - (3 ’ -ARYL-1 ’ -N -PHENYL-
PYRAZOL-4’-YL)-PYRIMIDINES.
Due to other properties 107-155 and biodynamic activities 47-106 of pyrimidines
and with a view to have potent therapeutic agents, the synthesis of 4-amino-2-
methylsulphonyl-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-pyrim-
idines (Va-h) have been undertaken by the reaction of different 4-amino-2-
methylthio-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro-
pyrimidines with hydrogen peroxide .
The constitution of the products (Va-h) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (Va-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
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IR  SPECTRAL  STUDY  OF   4-AMINO-2-METHYLSULPHONYL-5-CARBETHOXY-
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(Va-h) R = Aryl




PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-
METHYLSULPHONYL-5 -CARBETHOXY-6 - (3 ’ -ARYL-1 ’ -N -PHENYL-
PYRAZOL-4’-YL)-PYRIMIDINES.
(A) Preparation of 4-amino-2-mercapto-5-carbethoxy-6-[3’-(p-methoxy
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (Ib) .
For preparation refer Part-I, Section-I, Page No. 43.
(B) Preparation of 4-amino-2-methylthio-5-carbethoxy-6-[3’-(p-methoxy
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (IVb).
For preparation refer Part-I, Section-IV, Page No. 77.
(C) Preparation of 4-amino-2-methylsulphonyl-5-carbethoxy-6-[3’-(p-
methoxy phenyl)-1’-N-phenyl-pyrazol-4’-yl]-pyrimidine (Vb).
4-amino-2-methylthio-5-carbethoxy-6-[3’-(p-methoxy phenyl)-1’-N-
phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine  (4.63 gm, 0.01M) was dissolved
in 20ml of glacial acetic acid and add 12 ml of hydrogen peroxide  and then
kept for 48 hrs. at room temperature. The content was poured into ice cold
water and filtered. The product was isolated and crystallized from ethanol. Yield
: 63%, M.P. : 245°C, R f1
 : 0.41, R f2
 : 0.46 (Required : C, 58.41%; H, 4.70%; N,
14.20% for C24H23N5O5S, Found : C, 58.36 %; H, 4.64%; N, 14.15%).
Similarly, other compounds (Va-h) were synthesized. The physical data
are recorded in Table No. 5.
(D) Antimicrobial activity of 4-amino-2-methylsulphonyl-5-carbethoxy-
6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-pyrimidines (Va-h).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 5a, 5b & 5c.




















































































































































































































































































































































































































   
   
   
   




   












   




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-[(2”,4”-
DINITROPHENYL)THIO]-5-CARBETHOXY-6-(3’ -ARYL-1’-N-PHENYL-
PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
Due to other properties 107-155 and biodynamic activities47-106 of pyrimidines
and with a view to have potent therapeutic agents, the synthesis of 4-amino-2-
[(2”,4”-dinitrophenyl)thio]-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-
yl)-1,6-dihydro pyrimidines  (VIa-h) have been undertaken by the reaction of
different 4-amino-2-mercapto-5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-
yl)-1,6-dihydro pyrimidines  with 2,4-dinitro chloro benzene  in the presence
of base .
The constitution of the products (VIa-h) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (VIa-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
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IR  SPECTRAL  STUDY  OF   4-AMINO-2-[(2”,4”-DINITRO PHENYL)THIO]-
5-CARBETHOXY- 6-[ 3’-(p-METHOXY PHENYL)-1’-N-PHENYL-PYRAZOL-
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PMR SPECTRAL STUDY OF  4-AMINO-2-[(2”,4”-DINITRO PHENYL)THIO]-
5-CARBETHOXY-6-[3’-(p-METHOXY PHENYL)-1’-N-PHENYL-PYRAZOL-4’-































































































































































































































































































































 (VIa-h) R = Aryl




PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-[(2”,4”-
DINITRO PHENYL)THIO]-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-
PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
(A) Preparation of 4-amino-2-mercapto-5-carbethoxy-6-[3’-(p-methoxy
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (Ib) .
For preparation refer Part-I, Section-I, Page No. 43.
(B) Preparation of 4-amino-2-[(2”,4”-dinitro phenyl)thio]-5-carbethoxy-
6-[3’-(p-methoxyphenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro
pyrimidine (VIb).
A mixture of 4-amino-2-mercapto-5-carbethoxy-6-[3’-(p-methoxy phenyl)-
1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine  (4.49 gm, 0.01 M) and 2,4-
dinitro chlorobenzene  (2.02 gm, 0.01 M) in ethanol (30 ml) and add 2 ml of
10% aqueous sodium hydroxide  was heated under refluxed condition for three
hrs. The content was poured into ice cold water and filtered. The product was
isolated and crystallized from ethanol. Yield : 52%, M.P. : 206°C, Rf1
 : 0.49,
Rf2
 : 0.63 (Required : C, 56.58%; H, 4.09%; N, 15.93% for C29H25N7O7S,
Found : C, 56.52%; H, 4.02%; N, 15.90%).
Similarly, other compounds (VIa-h) were synthesized. The physical data
are recorded in Table No. 6.
(C) Antimicrobial activity of 4-amino-2-[(2”,4”-dinitro phenyl)thio]-5-
carbethoxy-6- (3 ’ -aryl -1 ’ -N-phenyl -pyrazol -4 ’ -y l ) -1 ,6-dihydro
pyrimidines (VIa-h).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 6a, 6b & 6c.
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PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-[(2”,4”-
DINITROPHENYL)SULPHONYL]-5-CARBETHOXY-6-(3’-ARYL-1’-N-PHENYL-
PYRAZOL-4’-YL)-PYRIMIDINES.
Due to other properties 107-155 and biodynamic activities47-106 of
pyrimidines and with a view to have potent therapeutic agents, the synthesis
of 4-amino-2-[(2”.4”-dinitrophenyl)sulphonyl]-5-carbethoxy-6-(3’-aryl-1’-
N-phenyl-pyrazol-4’-yl)-pyrimidines (VIIa-h) have been undertaken by the
reaction of different 4-amino-[(2”.4”-dinitrophenyl)thio]-5-carbethoxy-6-(3’-
aryl-1’-N-phenyl-pyrazol-4’-yl)-1,6-dihydro pyrimidines with hydrogen
peroxide.
The constitution of the products (VIIa-h) have been delineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (VIIa-h) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
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(VIIa-h) R = Aryl




PREPARATION AND BIOLOGICAL SCREENING OF 4-AMINO-2-[(2”,4”-
DINITRO PHENYL)SULPHONYL]-5-CARBETHOXY-6-(3’ -ARYL-1’ -N-
PHENYL-PYRAZOL-4’-YL)-PYRIMIDINES.
(A) Preparation of 4-amino-2-mercapto-5-carbethoxy-6-[3’-(p-methyl
phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine (Ic) .
For preparation refer Part-I, Section-I, Page No. 43.
(B) Preparation of 4-amino-2-[(2”,4”-dinitro phenyl)thio]-5-carbethoxy-
6-[3’-(p-mthyl phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro-
pyrimidine (VIc).
For preparation refer Part-I, Section-IV, Page No. 99.




phenyl)-1’-N-phenyl-pyrazol-4’-yl]-1,6-dihydro pyrimidine  (5.99 gm, 0.01M)
was dissolved in 20ml of glacial acetic acid and add 12 ml of hydrogen
peroxide  and then kept for 48 hrs. at room temperature. The content was poured
into ice cold water and filtered. The product was isolated and crystallized from
ethanol. Yield : 63%, M.P. : 237°C, R f1
 : 0.78, R f2
 : 0.58 (Required : C, 55.32%;
H, 3.65%; N, 15.58% for C 29H23N7O8S, Found : C, 55.28 %; H, 3.61%; N,
15.55%).
Similarly, other compounds (VIIa-h ) were synthesized. The physical data
are recorded in Table No. 7.
(D) Antimicrobial activity of 4-amino-2-[(2”,4”-dinitro phenyl)sulphonyl]-
5-carbethoxy-6-(3’-aryl-1’-N-phenyl-pyrazol-4’-yl)-pyrimidines  (VIIa-h ).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 7a, 7b & 7c.
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Pyrazolo[3,4-d]pyrimidine (42) is a fused heterocyclic compound in
which pyrimidine with its “d” position is fused at 3,4-position of pyrazole  ring.R.
Justoni et al.,159  have synthesized 6-methyl-1,3-diphenyl-1H-pyrazolo[3,4-d]-
pyrimidine -4-(5H)-ones in 1938. Pyrazolo[3,4-d]pyrimidine  ring is isomeric
with the purine  (43) ring and therefore, is of interest as a model for biologically



















Pyrazolo[3,4-d]pyrimidine Purine ring system
There are two other possible isomers of pyrazolo[3,4-d]pyrimidines,
which are fused at different positions of pyrazole  ring and are represented as
under.













METHODS FOR SYNTHESIS OF PYRAZOLO[3,4-d]PYRIMIDINES
Extensive studies have been made in the field of synthesis of pyrazolo[3,4-d]-
pyrimidines . Various methods for the synthesis of pyrazolo[3,4-d]pyrimidines
have been described as under:
(a) By the condensation of 5-amino-4-cyano-pyrazole with 5-nitro-2-
furonitrile  led to formation of 4-amino-6-(5’-nitro-2’-furyl)-1H-
pyrazolo[3,4-d]pyrimidines 160.
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(b) By the cyclocondensation of 4,6-dichloro-5-formylpyrimidine with
hydrazine hydrate led to formation of 1H-pyrazolo[3,4-d]pyrimidines 161 .
(c) By the fusion of 1,3-dimethyl-6-hydrazino uracil at 150oC with dimethyl
formamide dimethylacetal (DMFDMA)  led to formation of 2-alkyl-5,7-
dimethyl pyrazolo[3,4-d]pyrimidine-4,6(5H, 7H)-diones 162.
(d) By the fusion of 5-arylazo-6-arylidene-hydrazino-1,3-dimethyl uracils
at 200oC led to formation of 2-benzyl-5,7-dimethyl-3-phenyl pyrazolo-
[3,4-d]pyrimidines-4,6(5H,7H)-diones 163.
(e) By the cyclocondensation of 5-amino-4-cyano pyrazole with guanidine
carbonate led to formation of 4,6-diamino pyrazolo[3,4-d]pyrimidines164 .
(f) By the cyclocondensation of arylidene derivative of 1,3-diphenyl uracil
with hydrazine hydrate  led to the formation of pyrazolo[3,4-d]-
pyrimid ines  165.
(g) By the cyclocondensation of 4-carboxamido-5-amino-1,2,3-trihydro-
pyrazole with formamide led to the formation of pyrazolo[3,4-d]-
pyrimidines 166.
(h) By the cyclocondensation of 3,4-dicyano-5-amino-1-N-substitied
pyrazole with trichloro acetonitrile  led to formation of pyrazolo[3,4-d]-
pyrimidines 167.
(i) By the cyclocondensation of 3-aryl-2-arylamino-5-cyano-6-methyl-
sulphonyl pyrimidine-4-one  with hydrazine hydrate   led to formation
of pyrazolo[3,4-d]pyrimidines 168.
(j) By the cyclization of 2-chloro-6-methoxy quinoline-3-carboxaldehyde
and 3-methyl-1-N-phenyl-5-pyrazolone  with thiourea led to formation
of pyrazolo[3,4-d]pyrimidines 169.
Pyrazolo[3,4-d]pyrimidines were found to possess remarkable
biological activity viz. 1-aryl-3-methyl-6-mercapto-4,5-dihydro pyrazolo[3,4-d]-
pyrimidine (46) shows fungicidal 170  activity, [1,6-dimethyl-5-(2-methyl
phenyl) -1,5-dihydro pyrazolo[3,4-d]pyrimidine-4-ylidine]methyl aniline  (47)
shows  pesticidal 171,172  activity and  6-[aryl(diflouro)methyl)-3-aryl-1,5-
dihydro pyrazolo[3,4-d]pyrimidine-4-one  shows (48) herbicidal 173  activities.
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R=ph/4-CI-C 6H4
PHARMACOLOGICAL SIGNIFICANCE OF PYRAZOLO[3,4-d]PYRIMIDINES
Considerable research has been undertaken to extend the activity and
reduce toxicity of Pyrazolo[3,4-d]pyrimidine . The specific biological activities
have been represented as under.
(a) Hyperuricemia 174,175 (b) Protozoacidal 176
(c) Hypoglycemic 177 (d) Antimalarial 178
(e) Anticancer 179-182 (f) Analgesic, antipyretic,
antiinflammatory 183-186
(g) Antimycotic agent 187 (h) Xanthine oxidase inhibitor 188,189
(i) Antitumor 190-192 (j) AntiHIV 193
(k) Anxiolytic agent 194 (l) Cardiovascular 195,196
(m) Antileishmanial 197-199 (n) Tranquilizer 200
(o) Blood sugar lower agent 201 (p) Antiparasitic 202
(q) Antianaphylactic agent 203 (r) Coccidiostatic agent 204
(s) Anticonvulsant 205 (t) Antiviral 206
(u) Antiallergic 207
F. Robert et al., 208 have conducted the studies of pyrazolo[3,4-d]-
pyrimidine as a chemotherapeutic agent against neurospora. The family of 4-
amino pyrazolo[3,4-d]pyrimidines linked at 3 and 1 position by pyridoxine
and pyridoxamine which are involved in a thiamine metabolism and which are
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linked by series of related compounds adenine, thiamine, caffeine  and some
vitamins can exhibit neurospora growth. E. Harward et al.,209 evaluated 4-
amino pyrazolo[3,4-d]pyrimidines and its methyl derivative as significant
growth inhibitor of adrenocarcinoma 755 in mice. Machon et al.,220  have  syn-
thesized pyrazolo[3,4-d]pyrimidines (49) which possess carcinostatic activ-
ity at 50 mg/kg gave 71 to 76% inhibitor respective of Ehrlich Carcinoma in
mice.Dobrynine et al.,211  have tested 3,4-disubstituted-6-(methylmercapto)
pyrazolo[3,4-d]pyrimidines (50) for cytotoxic activity on a human overiancarcinoma


















Fusishita et al.,212 have synthesized pyrazolo[3,4-d]pyrimidines (51)
as angiotensin (II) antagonists.R. P. Tripathi et al.,213  have synthesized 2',2'-
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M.L. Taha et al.,214 have synthesized 1-(2-hydroxy ethoxymethyl)
pyrazolo[3,4-d]pyrimidines  (53) as antiHIV agents.Oocta et al., 215  have pre-
pared 1H-pyrazolo[3,4-d]pyrimidines (54) as potent antihypertensive and
cardiovascular agent.


















Y. Xia et al.,216  have synthesized polycyclic pyrazolo[3,4-d]pyrimidines
(55) and evaluated as PDE-1, PDE-5, CGMF-phosphodiesterase inhibitor. This
compound was also good orally active antihypertensive in laboratory.A. Straub















Recently,  A.S. Bell et al.,218 have prepared pyrazolo[3,4-d]pyrimidines
(57) are useful for treatment of memory enhancement, hypertension, congestive
heart failure and female sexual dysfunction.













M. Friedman et al.,219  have prepared 3-(azo hetero)aryl-1H- pyrazolo













J. Markwalder et al.,220  have synthesized 6-substitited pyrazolo[3,4-
d]- pyrimidin-4-ones (59) useful as cyclin dependent Kinase (cdk) inhibitors
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The most successful and well-understood compound pyrazolo[3,4-d]-
pyrimidines is acyclovir (60),which is highly active against herpes simplex
virus (HSV) and varicella zoster virus  infections, and is used clinically. 221,222
Acyclovir is a 2’-deoxyguanosine analoge  that contains an acyclic side chain
in the place of the deoxyrebose ring. It contains all of the atoms of 2’-
deoxyguanosine , with the exception of the 2’- and 3’-carbons and 3’-hydroxy









Like most nucleoside analogess, acyclovir is a prodrug. Unlike other
necleoside analogs such as 3-Azido-3’deoxythymidine(AZT) , however, prodrug
activation is one of the mechanisms by which acyclovir obtains selectivity. The
compound has a selectivity index of approximately 3000; the IC 50 is 300mM for
inhibition of HSV-1, while the IC 50 is 300mM for cytotoxicity to host Vero cells
in vitro.221  This selectivity is derived from two different mechanisms: differen-
tial activation of acyclovir in infecte cells and increased potency against HSV
DNA polymerase . Acyclovir is phosphorylated 30-120 times faster with extracts
from HSV-1-infected cells compared with uninfected cell extracts.222  Moreover,
the K i values for HSV-encoded DNA polymerases are 10-40 times lower than
for cellular DNA polymerases.221  Thus the active form of acyclovir is present
in greter quntities within virally infected cells and is also more potent against
viral DNA polymerase.
Acivation of acyclovir to its triphosphate form is mediated by both viral
and cellular enzymes. Virally encoded thymidine kinase produces acyclovir
monophosphate , which is further phosphoryalated by cellular GMP kinase to
the diphosphate derivative. The diphosphate is converted to acyclovir triph-
osphate , the derivatie, by cellular kinases such as phosphoglycerate kinase.
There are several lines of evidence that support HSV thymidine kinase as a
keyenzyme for the antiviral effect of acyclovir.221  Perhaps the most convinc-
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ing evidence is derived from studies with  thymidine kinase-deficient mutants of
HSV , which are resistant to acyclovir because no phosphorylation occurs within
infected cells.
The triphosphate form of acyclovir onhibits DNA polymerase. The mecha-
nism of inhibition is complex and may involve enzyme inactivation.223  Initially,
the compound competes with dGTP for binding to the polymerase-template com-
plex. Following binding, it has beensuggested that enzyme inactivation occurs
by the formation of a tight,irreversible enzyme-DNA-acyclovir triphosphate ter-
nary complex. Addition of dGTP to this complex does not release active viral
DNA polymerase. Interestingly, DNA polymerase a fromthe host cell is not inacti-
vated in this manner. In addition to dGTP compiition and enzymeinactivation,acyclovir
triphosphate inactivates the viral DNA template by chain termination, since it
does not contain the 3’-OH group necessary for the addition of subsequent
dNTPs.224 In virally infected cells, incomplete DNA replication occurs upon
treatment with acyclovir.225
Several analoges of acyclovir have been investigated, both at the
level of the target enzymes and for antiviral effect. Various alterations to the
aliphatic side chain of acyclovir are tolerated by the HSV thymidine kinase, as
long as the terminal hydroxy group is retained for phosphorylation.226 However,
the enzyme is far less tolerant of modification to the heterocyclic base moiety.
Since pyrimidine are the natural substrates for the viral thymidine kinase, it
seemed logical to predict that pyrimidine analogs of acyclovir might be good
kinase substrates and antiviral activity. However, this is not the case. Similarly,
among purine analogs, only those containing guanine are good substrates for
the viral  enzyme.226
Gaciclovir (61) is an acyclovir analogs that contains an additional
hydroxymethyl group in the side chain.227  Because this compound contains
groups that mimic both the 5’-OH and 3’-OH groups of deoxyguanosine, it
does not act as a chain terminator for DNA synthesis. Nevertheless, compound
(61) is selectively phosphorylated by the viral thymidine kinase and, as the triph-
osphate form, inhibits Herpes Simplex virus-1(HSV-1 , HSV-2)  polymerase.238
Gaciclovir  has been reported to be superior to acyclovir against human cy-
tomegalovirus  (HCMV) .  Although the compound is converted to the
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triphosphateform in HCMV- infected  cells, the enzymes responsible for this trans-
formation are not yet known. There is no evidence that HCMV  encodes a thymi-
dine kinase.
Among acyclovir analogs, the cyclic monophosphate derivative (8)
has been reported to have the broadest spectrum of activity against DNA vi-
ruses.222,229  Within cells, compound  (62) is converted to the (S) enantiomer
of ganciclovir monophosphate  (63), the same compound that is obtained from
phosphorylation of (61) by HSV-1 thymidine kinase.Other analogs that have
been prepared include compound (64) and a series of related derivatives.222,230







































(61)     (62)    (63) (64)
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on pyrazolo[3,4-d]pyrimidines for their various methods of
synthesis and different pharmacological activities, synthesis of pyrazolo
[3,4-d]pyrimidines have been undertaken which can be summarized in the fol-
lowing section as under.
SECTION  - I : PREPARATION AND BIOLOGICAL SCREENING OF 3-
AMINO-4-ARYL-6-MERCAPTO-1-N-PHENYL-4,5-DIHYDRO-
PYRAZOLO[3,4-d]PYRIMIDINES .
SECTION  - II : PREPARATION AND BIOLOGICAL SCREENING OF 3-
AMINO-4-ARYL-6-HYDROXY-1-N-PHENYL-4,5-DIHYDRO-
PYRAZOLO[3,4-d]PYRIMIDINES .
SECTION  - III : PREPARATION AND BIOLOGICAL SCREENING OF 3,6-





SECTION  - IV : PREPARATION AND BIOLOGICAL SCREENING OF 3-
AMINO-4-ARYL-6-METHYLTHIO-1-N-PHENYL-4,5-DIHYDRO-
PYRAZOLO[3,4-d]PYRIMIDINES .
SECTION  - V : PREPARATION AND BIOLOGICAL SCREENING OF 3-
AMINO-4-ARYL-6-METHYLSULPHONYL-1-N-PHENYL-
PYRAZOLO[3,4-d]PYRIMIDINES.
SECTION  - VI : PREPARATION AND BIOLOGICAL SCREENING OF 3-
AMINO-4-ARYL-6-[(2’,4’-DINITROPHENYL)THIO]-1-N-
PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES.
SECTION  - VII : PREPARATION AND BIOLOGICAL SCREENING OF 3-
AMINO-4-ARYL-6-[(2’,4’-DINITRO PHENYL)SULPHONYL]-
1-N-PHENYL-PYRAZOLO[3,4-d]PYRIMIDINES.




PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-MERCAPTO-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES .
In view of various biodynamic activities 174-206 , other  properties207-230
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3-amino-4-aryl-6-mercapto-1-N-phenyl-4,5-dihydro
pyrazolo[3,4-d]pyrimidines (VIIIa-j) have been undertaken by the condensation









(VIIIa-j)                 R=Aryl
The constitution of the products (VIIIa-j)  have been delineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (VIIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
compounds were compared with standard drugs.
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IR  SPECTRAL  STUDY  OF  3-AMINO-4-(p-CHLORO PHENYL)-6-MERCAPTO-
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   (VIIIa-j) R = Aryl




PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-MERCAPTO-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES .
(A) Preparation of 3-amino-4-(p-chloro phenyl)-6-mercapto-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (VIIIe) .
A mixture of 4-chloro benzaldehyde  (1.40gm, 0.01 M), 3-amino-1-N-
phenyl-5-pyrazolone (1.75 gm, 0.01 M) and thiourea (0.76 gm, 0.01 M) in
ethanol (30 ml) was heated under refluxed condition for three hrs. Then the
reaction mixture was kept at room temperature for two hrs. The yellow crystal-
line product  so obtained  was isolated and recrystallized from ethanol. Yield :
59%, M.P. : 104°C, R f1
 : 0.68, R f2
 : 0.54 (Required :  C: 57.38%; H: 3.97%; N:
19.69% for C 17H14ClN5S, Found : C: 57.33%; H: 3.91%; N:19.64% ).
Similarly, other compounds (VIIIa-j) were synthesized. The physical data
are recorded in Table No. 8.
(B) Antimicrobial activity of 3-amino-4-aryl-6-mercapto-1-N-phenyl-4,5-
dihydro pyrazolo[3,4-d]pyrimidines (VIIIa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 8a, 8b & 8c.
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PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6- HYDROXY-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES .
In view of various biodynamic activities174-206 , other  properties 207-230
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3-amino-4-aryl-6-hydroxy-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidines (IXa-j)  have been undertaken by the condensa-
tion of different aromatic aldehydes  with 3-amino-1-N-phenyl-5-pyrazolone
and  urea.
The constitution of the products (IXa-j)  have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IXa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory Concentration) values. The biological activities of the synthesized








(IXa-j)                 R=Aryl
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PMR SPECTRAL STUDY OF  3-AMINO-4-(p-METHOXY PHENYL)-6-HYDROXY-























































































































































































































































































   (IXa-j) R = Aryl




PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-HYDROXY-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES .
(A) Preparation of 3-amino-4-(p-methoxy phenyl)-6-hydroxy-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (IXh).
A mixture of 4-methoxy benzaldehyde  (1.36ml, 0.01 M), 3-amino-1-N-
phenyl-5-pyrazolone  (1.75 gm, 0.01 M) and urea (0.60 gm, 0.01 M) in ethanol
(30 ml) was heated under refluxed condition for three hrs. Then the reaction
mixture was kept at room temperature for two hrs. The yellow crystalline product
so obtained  was isolated and recrystallized from ethanol. Yield : 48%, M.P. :
109°C, Rf1
 : 0.68, R f2
 : 0.64 (Required :  C: 64.47%; H: 5.11 %; N: 20.90% for
C18H17N5O2, Found : C: 64.42%; H: 5.06%; N:20.85% ).
Similarly, other compounds (IXa-j) were synthesized. The physical data
are recorded in Table No. 9.
(B) Antimicrobial activity of 3-amino-4-aryl-6-hydroxy-1-N-phenyl-4,5-
dihydro pyrazolo[3,4-d]pyrimidines (IXa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 9a, 9b & 9c.
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PREPARATION AND BIOLOGICAL SCREENING OF 3,6-DIAMINO-4-
ARYL-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES .
In view of various biodynamic activities 174-206 , other  properties207-230
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3,6-diamino-4-aryl-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidines (Xa-j) have been undertaken by the condensation
of different aromatic aldehydes with 3-amino-1-N-phenyl-5-pyrazolone and
guanidine hydrochloride .
The constitution of the products (Xa-j)  have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (Xa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized








(Xa-j)                 R=Aryl















































IR  SPECTRAL  STUDY  OF   3,6-DIAMINO-4-(p-METHOXY PHENYL)-1-N-



































































S t u d i e s  o n  P y r azolo[3,4-d]pyrimidines
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
156
PMR SPECTRAL STUDY OF  3,6-DIAMINO-4-(p-METHOXY PHENYL)-1-N-
























































































































































































































































































   (Xa-j) R = Aryl




PREPARATION AND BIOLOGICAL SCREENING OF 3,6-DIAMINO-4-
ARYL-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3,6-diamino-4-(p-methoxy phenyl)-1-N-phenyl-4,5-
dihydro pyrazolo[3,4-d]pyrimidine (Xh).
A mixture of 4-methoxy benzaldehyde  (1.36ml, 0.01 M), 3-amino-1-N-
phenyl-5-pyrazolone  (1.75 gm, 0.01 M) and guanidine hydrochloride  (0.95
gm, 0.01 M) in ethanol (30 ml) was heated under refluxed condition for three
hrs. Then the reaction mixture was kept at room temperature for two hrs. The
yellow crystalline product  so obtained  was isolated and recrystallized from
ethanol. Yield : 52%, M.P. : 120°C, Rf1
 : 0.58, Rf2
 : 0.64 (Required :  C: 64.66%;
H: 5.43%; N: 25.15% for C 18H18N6O, Found : C: 64.61%; H: 5.39%; N:25.10% ).
Similarly, other compounds (Xa-j) were synthesized. The physical data
are recorded in Table No. 10.
(B) Antimicrobial activity of 3,6-diamino-4-aryl-1-N-phenyl-4,5-dihydro
pyrazolo[3,4-d]pyrimidines (Xa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 10a, 10b & 10c.
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PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-METHYLTHIO-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES.
In view of various biodynamic activities 174-206 , other  properties207-230
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3-amino-4-aryl-6-methylthio-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidines (XIa-j) have been undertaken by the reaction
of different 3-amino-4-aryl-6-mercapto-1-N-phenyl-4,5-dihydro pyrazolo[3,4-d]-
pyrimidines  with dimethyl sulphate  in the presence of base.
The constitution of the products (XIa-j)  have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory Concentration) values. The biological activities of the synthesized









(XIa-j)                 R=Aryl
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IR  SPECTRAL  STUDY  OF   3-AMINO-4-(p-CHLORO PHENYL)-6-METHYLTHIO-
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   (VIIIa-j)
   (XIa-j) R = Aryl




PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-METHYLTHIO-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3-amino-4-(p-chloro phenyl)-6-mercapto-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (VIIIe) .
For preparation refer Part-II, Section-I, Page No. 138 .
(B) Preparation of 3-amino-4-(p-chloro phenyl)-6-methylthio-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (XIe).
A mixture of 3-amino-4-(p-chloro phenyl)-6-mercapto-1-N-phenyl-4,5-
dihydro pyrazolo[3,4-d]pyrimidine(3.55 gm, 0.01 M) and dimethyl sulphate
(1.26 ml, 0.01 M) in ethanol (30 ml) and 40% aqueous sodium hydroxide
was stirred for 12 hrs. at room temperature. The content was poured into ice
cold water and filtered. The product was isolated and crystallized from ethanol.
Yield : 52%, M.P. : 164°C; Rf1
 : 0.61, Rf2
 : 0.62 (Required : C, 58.45%; H,
4.36%; N, 18.94% for C18H16ClN5S, Found : C, 58.41%; H, 4.30%; N, 18.88%).
Similarly, other compounds (XIa-j) were synthesized. The physical data
are recorded in Table No. 11.
(C) Antimicrobial activity of 3-amino-4-aryl-6-methylthio-1-N-phenyl-4,5-
dihydro pyrazolo[3,4-d]pyrimidines (XIa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 11a, 11b & 11c.




























































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




   












   
   







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-METHYLSULPHONYL-1-N-PHENYL-PYRAZOLO[3,4-d]PYRIMIDINES.
In view of various biodynamic activities 174-206, other  properties 207-230
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3-amino-4-aryl-6-methylsulphonyl-1-N-phenyl-
pyrazolo[3,4-d]pyrimidines (XIIa-j) have been undertaken by the reaction of
different 3-amino-4-aryl-6-methylthio-1-N-phenyl-4,5-dihydro pyrazolo[3,4-d]-
pyrimidines with hydrogen peroxide .
The constitution of the products (XIIa-j)  have been del ineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (XIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory Concentration) values. The biological activities of the synthesized











(XIIa-j)                 R=Aryl
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   (XIIa-j) R = Aryl
   (XIa-j)




PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-METHYLSULPHONYL-1-N-PHENYL-PYRAZOLO[3,4-d]PYRIMIDINES .
(A) Preparation of 3-amino-4-(p-methoxy phenyl)-6-mercapto-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (VIIIh).
For preparation refer Part-II, Section-I, Page No. 138 .
(B) Preparation of 3-amino-4-(p-methoxy phenyl)-6-methylthio-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (XIh).
For preparation refer Part-II, Section-IV, Page No. 171 .
(C) Preparation of 3-amino-4-(p-methoxy phenyl)-6-methylsulphonyl-1-
N-phenyl-pyrazolo[3,4-d]pyrimidine (XIIh).
3-amino-4-(p-methoxy phenyl)-6-methylthio-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidine  (3.65 gm, 0.01M) was dissolved in 20ml of glacial
acetic acid and add 12 ml of hydrogen peroxide  and then kept for 48 hrs. at
room temperature. The content was poured into ice cold water and filtered. The
product was isolated and crystallized from ethanol. Yield : 49%, M.P. : 124°C,
Rf1
 : 0.50, Rf2
 : 0.63 (Required : C, 57.71%; H, 4.33%; N, 17.72% for
C19H17N5O3S, Found : C, 57.65 %; H, 4.29%; N, 17.68%).
Similarly, other compounds (XIIa-j) were synthesized. The physical data
are recorded in Table No. 12.
(D) Antimicrobial activity of 3-amino-4-aryl-6-methylsulphonyl-1-N-phenyl-
pyrazolo[3,4-d]pyrimidines (XIIa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 12a, 12b & 12c.













































































   



















































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   





   












   














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-[(2’,4’-DINITROPHENYL)THIO]-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO-
[3,4-d]PYRIMIDINES.
In view of various biodynamic activities 174-206 , other  properties207-230
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3-amino-4-aryl-6-[(2’,4’-dinitrophenyl)thio]-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidines (XIIIa-j)  have been undertaken by the
reaction of different 3-amino-4-aryl-6-mercapto-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidines  with 2,4-dinitro chloro benzene  in the presence
of base.
The constitution of the products (XIIIa-j)   have been delineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (XIIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
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IR  SPECTRAL  STUDY  OF   3-AMINO-4-(p-CHLORO PHENYL)-6-[(2”,4”-DINITRO
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PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-[(2’,4’-DINITRO PHENYL)THIO]-1-N-PHENYL-4,5-DIHYDRO PYRAZOLO-
[3,4-d]PYRIMIDINES .
(A) Preparation of 3-amino-4-(p-chloro phenyl)-6-mercapto-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (VIIIe) .
For preparation refer Part-II, Section-I, Page No. 138 .
(B) Preparation of 3-amino-4-(p-chloro phenyl)-6-[(2’,4’-dinitro phenyl)thio]-
1-N-phenyl-4,5-dihydro pyrazolo[3,4-d]pyrimidine (XIIIe) .
A mixture of 3-amino-4-(p-chloro phenyl)-6-mercapto-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (3.55 gm, 0.01 M) and 2,4-dinitro chloro
benzene  (2.02 gm, 0.01 M) in ethanol (30 ml) and add 2 ml of 10% aqueous
sodium hydroxide was heated under refluxed condition for three hrs. The
content was poured into ice cold water and filtered. The product was isolated
and crystallized from ethanol. Yield : 38%, M.P. : 158°C, R f1
 : 0.52, R f2
 : 0.60
(Required : C, 52.93%; H, 3.09%; N, 18.79% for C 23H16ClN7O4S, Found :
C, 52.89%; H, 3.03%; N, 18.74%).
Similarly, other compounds (XIIIa-j) were synthesized. The physical data
are recorded in Table No. 13.
(C) Antimicrobial activity of 3-amino-4-aryl-6-[(2’,4’-dinitro phenyl)thio]-
1-N-phenyl-4,5-dihydro pyrazolo[3,4-d]pyrimidines (XIIIa-j) .
Antimicrobial activity test was carried out as described in part-I,section-I,
page No. 43. The MIC values of test solution are recorded in Table No. 13a,
13b & 13c.
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PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-[(2’ ,4’ -DINITRO PHENYL)SULPHONYL]-1-N-PHENYL-PYRAZOLO-
[3,4-d]PYRIMIDINES.
In view of various biodynamic activities 174-206, other  properties 207-230
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3-amino-4-aryl-6-[(2’,4’-dinitro phenyl)- sulphonyl]-
1-N-phenyl-pyrazolo[3,4-d]pyrimidines(XIVa-j) have been undertaken by the
reaction of different 3-amino-4-aryl-6-[(2’,4’-dinitro phenyl)thio]-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidines with hydrogen peroxide .
The constitution of the products (XIVa-j)  have been delineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (XIVa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
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PREPARATION AND BIOLOGICAL SCREENING OF 3-AMINO-4-ARYL-
6-[(2’,4’-DINITRO PHENYL)SULPHONYL]-1-N-PHENYL-PYRAZOLO[3,4-d]-
PYRIMIDINES.
(A) Preparation of 3-amino-4-(p-chloro phenyl)-6-mercapto-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine (VIIIe) .
For preparation refer Part-II, Section-I, Page No. 138 .
(B) Preparation of 3-amino-4-(p-chloro phenyl)-6-[(2’,4’-dinitro phenyl)thio]-
1-N-phenyl-4,5-dihydro pyrazolo[3,4-d]pyrimidine (XIIIe) .
For preparation refer Part-II, Section-VI, Page No. 194 .
(C) Preparation of 3-amino-4-(p-chloro phenyl)-6-[(2’,4’-dinitro phenyl) -
sulphonyl]-1-N-phenyl-pyrazolo[3,4-d]pyrimidine (XIVe).
3-amino-4-(p-chloro phenyl)-6-[(2’,4’-dinitro phenyl)thio]-1-N-phenyl-
4,5-dihydro pyrazolo[3,4-d]pyrimidine  (5.21 gm, 0.01M) was dissolved in 20ml
of glacial acetic acid and add 12 ml of hydrogen peroxide  and then kept for
48 hrs. at room temperature. The content was poured into ice cold water and
filtered. The product was isolated and crystallized from ethanol. Yield : 67%,
M.P. : 196°C, R f1
 : 0.54, R f2
 : 0.62 (Required : C, 50.05%; H, 2.56%; N, 17.77%
for C23H14ClN7O6S, Found : C,   50.01 %; H, 2.52%; N, 17.71%).
Similarly, other compounds (XIVa-j) were synthesized. The physical data
are recorded in Table No. 14.
(D) Antimicrobial activity of 3-amino-4-aryl-6-[(2’,4’-dinitro phenyl)- sulphonyl]-
1-N-phenyl-pyrazolo[3,4-d]pyrimidines (XIVa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 14a, 14b & 14c.
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Pyrimido[4,5-d]pyrimidines(65) is a fused heterocyclic compound in which
one of the pyrimidine with its 4,5-position is fused with another pyrimidine het-






In 1938 F.Bergel et al.,231 have synthesized 1,4 (or 3,4)-dihydro-2,7-
dimethyl pyrimido[4,6-d] pyrimidine. Pyrimido[4,5-d]pyrimidine ring sys-
tem isomeric with the pteridine(66)ring and therefore, is of interest as a modal







There are other four possible isomers of pyrimido[4,5-d]pyrimidines












(69)    (70)
       9aH-Pyrimido[1,2-a]pyrimidine     4aH-Pyrimido[1,6-c]pyrimidine
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SYNTHETIC METHODS OF PYRIMIDO[4,5-d] PYRIMIDINE
Several attempts have been made for the synthesis of pyrimido[4,5-d]-
pyrimidines , some of them are describes as under.
(1) By the cyclocondensation of 4-thiomethyl-5-substituted uracil with
formamide  led to the formation of pyrimido [4,5-d]pyrimidines  232
(2) By the cyclocondensation of b -arylidene malononitrile  with thiourea
fol lowed by reaction in nitrogen  and oxygen  atmosphere led to the
formation of pyrimido[4,5-d] pyrimidines 233
(3) By the cyclocondensation of 4-(p-substituted phenylamino)-5-carboxamido
pyrimidine with arylisocynate led to the formation of pyrimido[4,5-d]-
pyrimidines 234
(4) By the cyclocondensation of 4-amino pyrimidine  with formamide  at 1500C
led to the formation of 2,4-disubstituted pyrimido[4,5-d] pyrimidines 235
(5) By the heating of 6-amino-5-(N-carboxy carboxamido)uracil led to the
formation of pyrimido [4,5-d] pyrimidines 236
(6) By the cyclocondensation of 4-amino-5-carboxamido-6-substituted pyrimidine
with ethylacetate led to the formation of pyrimido[4,5-d] pyrimidines 237
(7) By the cyclocondensation of 5-carbamoyl-2,4-pyrimidine diamine with 1,1,1-
triethoxy methane  and 1,1,1-triformamido methane  led to the formation
of pyrimido[4,5-d] pyrimidines 238
(8) By the cyclocondensation of 4-amino-5-cyano-6-aryl-2-thioxo(3H) pyrimidine
with carbondisulphide  led to the formation of 4-aryl-2,5,7-trithioxo-1,6,8-
trihydro pyrimido[4,5-d] pyrimidines 239
THERAPEUTIC IMPORTANCE OF PYRIMIDO[4,5-d]PYRIMIDINE
The pyrimido[4,5-d]pyrimidines  are reported to exhibit a wide variety of
therapeutic activities such as;
 (a) Diuretic 240-243  (b) Antihypertensive 244
 (c) CNS-depressant 245-246  (d) Antimalarial 247
 (e) Platelate aggregation 248  (f) Antibacterial 249-255
 (g) Anticonvulsant 256  (h) Antithrombicagent 257
 (i) Coronary vasodilator 258,259   (j) Antitumor 260
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A.Takamisawa et al.,261  have synthesized pyrimido benzothiazine(71)
as sedative and analgesic.Chaitanya dave et al.,262  have synthesised 3-substituted
2-thioxo-5,7-dimethyl pyrido[2,3-d]pyrimidine-4-(3H)-ones and their S-alkylation
(72) as dihydrofolate and antitumor agents.





















Aleen G. et al.,263  have synthesized  non classical 2-Amino-4-oxo-6-
(arylthio)ethyl pyrrolo[2,3-d] pyrimidines(73) as Antifolates.T.J.Delia et al.,264
have synthesised 6-benzyl or phenetyl -2,4-diamino-5,6,7,8-tetrahydro



















S.Yurugi et al.,265 have synthesized 5,7-disubstituted amino-2-phenyl
pyrimido[4,5-d] pyrimidines  (75) as diuretic.Recently, A. Nagarajan et al.,266  have
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Anita Devi et al.,267  have synthesized 2- amino-6,8-diphenyl-oxo-pyrimido[4,5-
d ] pyrimidine-7-thiones (77,78)  and screened for antifungal activity at different
















In view of procuring highly potent biodynamic agents and after reviewing
literature survey on pyrimido[4,5-d]pyrimidines  for their various methods of syn-
thesis and different biological activities, synthesis of pyrimido[4,5-d] pyrimidines
have been undertaken which can be summarized in the following sections as under.
SECTION  - I : PREPARATION AND BIOLOGICAL SCREENING OF 5-(4’-
NITRO PHENYL)-2-ARYL-7-MERCAPTO-1,2,3-TRIHYDRO-
PYRIMIDO[4,5-d]PYRIMIDINE-4-ONES .
SECTION  - II : PREPARATION AND BIOLOGICAL SCREENING OF 5-(4’-
NITRO PHENYL)-2-ARYL-2-METHYL-7-MERCAPTO-2,3-
DIHYDRO PYRIMIDO[4,5-d]PYRIMIDINE-4-ONES .




PREPARATION AND BIOLOGICAL SCREENING OF 5-(4’- NITRO
PHENYL)-2-ARYL-7-MERCAPTO-1,2,3-TRIHYDRO PYRIMIDO[4,5-d]-
PYRIMIDINE-4-ONES.
Due to other propert ies  261-267  and biodynamic act iv i t ies  240-260
of pyrimido[4,5-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 5-(4’-nitrophenyl)-2-aryl-7-mercapto-1,2,3-trihydro-
pyrimido[4,5-d]pyrimidine4-ones (XVa-j) have been undertaken by the con-
densation of 2-mercapto-4-amino-5-carboxamido-6-(p-nitro phenyl)-pyri-
midine with different aromatic aldehydes.
The constitution of the products (XVa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (XVa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized









( XVa-j )                             R=Aryl
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PREPARATION AND BIOLOGICAL SCREENING OF 5-(4’-NITRO PHENYL)-
2-ARYL-7-MERCAPTO-1,2,3-TRIHYDRO PYRIMIDO[4,5-d]PYRIMIDINE-4-
ONES .
(A) Preparation of 2-Mercapto-4-amino-5- carboxamido-6-(4’-nitro
phenyl)-pyrimidine.
2-Mercapto-4-amino-5-cyano-6-(4’-nitro phenyl)-1,6-dihydro pyrimi-
dine(2.75 gm, 0.01M) was dissolved in concentrated sulphuric acid (20ml)
below 5 oC and kept for 48 hrs. at room temperature. The content was poured
into ice cold water and filtered. The product was isolated and crystallized from
ethanol. Yield : 58%, M.P. : 168°C,   Rf1
 : 0.51, Rf2
 : 0.60 (Required :C,
45.36%; H, 3.11%; N, 24.04% for C11H9N5O3S, Found : C, 45.31%; H, 3.07%;
N, 23.98%).
(B) Preparation of 5-(4’-nitro phenyl)-2-(p-methoxy phenyl)-7-mercapto-
1,2,3-trihydro pyrimido[4,5-d]pyrimidine-4-one  (XVh).
A mixture of 2-Mercapto-4- amino-5carboxamido-6-(4’-nitro phenyl)-
pyrimidine  (2.91gm, 0.01M) and p-anisaldehyde  (1.36ml, 0.01M) in glacial
acetic acid (30 ml) was heated under reflux condition for six hrs. The content
was poured into ice cold water and filtered. The product was isolated and crys-
tallized from ethanol:dioxan (2:1). Yield : 46%, M.P. : 238°C, R f1
 : 0.82, R f2
 :
0.63 (Required :  C: 55.74%; H: 3.69%; N: 17.11% for C 19H15N5O4S, Found
: C: 55.69%; H: 3.62%; N:17.07% ).
.
Similarly, other compounds (XVa-j) were synthesized. The physical data
are recorded in Table No. 15.
(C) Antimicrobial activity of 5-(4’-nitrophenyl)-2-aryl-7-mercapto-1,2,3-
trihydro pyrimido[4,5-d]pyrimidine-4-one s (XVa-j) .
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 43. The MIC values of test solution are recorded in Table No.
15a, 15b,15c.






































































































































































































































































































































































































































































































   












   































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PREPARATION AND BIOLOGICAL SCREENING OF 5-(4’-NITRO PHE-
NYL)-2-ARYL-2-METHYL-7-MERCAPTO-2,3-DIHYDRO PYRIMIDO[4,5-d]-
PYRIMIDINE-4-ONES.
Due to other properties 261-267 and biodynamic activities 240-260  of
pyrimido[4,5-d]pyrimidines  and with a view to have potent therapeutic agents,
the synthesis of 5-(4’-nitro phenyl)-2-aryl-2-methyl-7-mercapto-2,3-dihydro-
pyrimido[4,5-d]pyrimidine-4-ones (XVIa-h) have been undertaken by the con-
densation of 2-mercapto-4-amino-5-carboxamido-6-(4’-nitrophenyl) pyrimidine










The constitution of the products (XVIa-h) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (XVIa-h) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
compounds were compared with standard drugs.
(XVIa-h) R=Aryl
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PREPARATION AND BIOLOGICAL SCREENING OF 5-(4’-NITRO
PHENYL)-2-ARYL-2-METHYL-7-MERCAPTO-2,3-DIHYDRO PYRIMIDO-
[4,5-d]PYRIMIDINE-4-ONES.
(A) Preparation of 2-Mercapto-4-amino-5- carboxamido-6-(4’-nitro
phenyl)-pyrimidine.
2-Mercapto-4-amino-5-cyano-6-(4’-nitro phenyl)-1,6-dihydro pyrimi-
dine(2.75 gm, 0.01M) was dissolved in concentrated sulphuric acid (20ml)
below 5 oC and kept for 48 hrs. at room temperature. The content was poured
into ice cold water and filtered. The product was isolated and crystallized from
ethanol. Yield : 58%, M.P. : 168°C,   Rf1
 : 0.51, Rf2
 : 0.60 (Required :C,
45.36%; H, 3.11%; N, 24.04% for C11H9N5O3S, Found : C, 45.31%; H, 3.07%;
N, 23.98%).
(B) Preparation of 5-(4’-nitro phenyl)-2-(p-methoxy phenyl)-2-methyl-7-
mercapto-2,3-dihydro pyrimido[4,5-d]pyrimidine-4-one (XVIb).
A mixture of 2-Mercapto-4- amino-5carboxamido-6-(4’-nitro phenyl)-
pyrimidine  (2.91gm, 0.01M) and p-methoxy acetophenone  (1.50ml, 0.01M)
in glacial acetic acid (30 ml) was heated under reflux condition for six hrs. The
content was poured into ice cold water and filtered. The product was isolated
and crystallized from ethanol:dioxan (2:1). Yield : 63%, M.P. : 155°C, Rf1
 :
0.61,  Rf 2
 :  0 .63 (Required :   C:  56.73%; H:  4 .05 % ;  N :  16.55% for
C20H17N5O4S, Found : C: 56.68%; H: 4.00%; N:16.50% ).
.
Similarly, other compounds (XVIa-h) were synthesized. The physical data
are recorded in Table No. 16
(C) Antimicrobial activity of 5-(4’-nitro phenyl)-2-aryl-2-methyl-7-
mercapto-2,3-dihydro pyrimido[4,5-d]pyrimidine-4-ones(XVIa-h).
Antimicrobial activity testing was carried out as described in part-1,sec-
tion-I, page No. 43. The MIC values of test solution are recorded in Table No.
16a, 16b, 16c.
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STUDIES ON 1,4-DIHYDRO PYRIDINE DERIVATIVES
INTRODUCTION
In 1,4- dihydropyridine  either imino (NH) or substituted nitrogen atom is
present at one position and hydrogen atom at four position of the six membered
hetrocyclic ring which can be represented as under. (79).
        R1 , R4  = H / Alkyl / Aryl
         R2 , R6  = Methyl
                                                            R3,R5  = Acetyl /Carbmethoxy/
                         Carbethoxy / N-Aryl Carbamoyl
1,4-dihydropyridine contribute as an important class of compound in
medicinal  chemistry,  leading to several new drugs currently  widely used especially as
calcium channel antagonist268  and other cardiovascular diseases also.
SYNTHETIC METHODS OF  1,4-DIHYDRO PYRIDINES
B.Chekavichus et al.275 has proposed following kind of successive












































(B)(C)R,R1= Alkyl / Aryl
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The synthesis of 1,4-dihydro pyridines  involves following steps.
(1) Intermediate (A) involves cyclisation of 3-aryl-aminocrotonate and arylidene
followed by the rearrangement of hydrogen.
(2) Intermediate (B) involves dehydration of  (A) with loss of equimolar quantity
of water.
(3) Intermediate (C) involves isomerisation of intermediate of (B) and obtained
regio and stereo selective 1,4-dihydro pyridine  as a final product .
It has been observed that in the presence of piperidine as a catalyst ,
pyran was formed as an intermediate by the cyclocondensation of aliphatic or
aromatic aldehydes  with 1,3-diketones , followed by the dehydration of pyran
through the reaction with aliphatic or aromatic amines affored final product.




































R, R3 = H / Aryl / Aryl
R1, R4 = Carboxylate/ Arylcarbamoyl






































































(1) Abstraction of proton by base  from ethyl aceto acetate  form nucleophile.
(2) Attack of nucleophile on aldehyde  molecule to yield bis-keto ester .
(3) Condensation of NH3 with bis-keto ester with removel of water molecule to
give 1,4 dihydro pyridine  derivative.
SYNTHETIC METHODS OF  1,4-DIHYDRO PYRIDINES
Different synthetic methods for the synthesis of 1,4-dihydropyridine  are
as follows.
(1) By the condensation of aromatic or aliphatic aldehydes with acetoacetate
ester and aromatic or aliphatic amine  in presence of pyridine269-272 .
(2) By the condensation of aliphatic or aromatic aldehydes with 3-amino
crotonate  and 1,3 -diketone  273-280 .
(3) By the condensation of arylidine  with 3-aminocrotonate281 .
(4) By the condensation of aliphatic or aromatic aldehydes  with various 1,3-
diketones  in presence of ammonia  or ammonium carbonate282-284 .
(5)        By the condensation of a.b  -unsaturated ketones  with malononitrile  and
cyanoacetamide 285  .
(6)       By the condensation of o-nitrobenzaldehyde, b  -amino butaricacid  and
methylpripiolate in glacial acetic acid286
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
(7) By the knoevenagel condensation of benzaldehyde  with acetoaceticester
in presence of b -alanine as catalyst and subsequent cyclocondensation
of theresulting benzylidene  with 3-amino crotonate287  .
(8)       By the regio and chemoselective addition of  Ph2Cu(CN)Li2 to substituted
N-alkyl pyridium salts followed by acylation of the intermediate 288  .
(9)       By the condensation of 1,3-diketones ,alkyl or aryl aldehydes with aqueous
ammonium hydroxide  in the presence of piperidine or piperidyl acetate
or potassium acetate or potassium carbonate or glacial acetic acid289-291  .
(10)    By the condensation of two moles of thiobarbituric acid , aromatic amines
and aromatic aldehydes292,293.
THERAPEUTIC IMPORTANCE OF 1,4-DIHYDRO PYRIDINES
The research on 1,4-dihydropyridine  system is of current interest due to
their valuable activities as calcium channel antagonist , vasodilator , cardio-
vascular etc. beside the currently established drugs Nifedipine294,295 ,
Nicardipine .296,297  Many dihydropyridine derivatives have been synthesized
world wide288,308 . and have led to numerous second generation commercial
product309,316. such as Nimodipine 317,318 , Nisodipine319 , Nitrendipine 320 ,
Amlodopine 321 ,  Felodip ine 322 ,  Isradipine 323 ,  Manidip ine 324  and
Nelvadipine 325 . Some of their compounds are characterized by longer bioactiv-
ity of greater tissue selectivity. 1,4-dihydropyridine  derivatives are associated
with diverse biological activities viz.
(a) Antiarythemic326 (b) Antiinflammatory327
(c) Antiallergic328 (d) Antiulcer329
(e) Antitumor270 (f) Vasodilator330
(g) Enzymetic331,332 (h)   Calcium channel antagonist 333-335
(i) Antihypertensive336,337 (j) Antihypolipemic338
(k) Antimayocardic ischemic339 (l) Cardiovascular340
(m) Photo induced relaxation274,284 (n) Antitubercular agents341
I. Nadeem et al. (80) have demonstrated the structure function relationship
of calcium channel and photo induced relaxation of novel 1,4- dihydro pyridines.
Activities of calcium channel antagonists invitro were detected and  gave
such conclusion about structure-activity relationship(SARs) .
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
(1) Relative potency order for C-4 phenyl substituents is ortho ans meta is
greater  then pera.





       (80)                R 1=COOCH3 / COOC2H5
      R2=COOCH3 / COOC2H5
    R3 =Substituted phenyl
G. Charles et al.342 (81) have synthesized 1,4-dihydropyridines for
















       (81)   (82)
Dihydro pyridine derivatives (81) have been found to be useful in treating
benign prostate hyperplasia inhibition of cholesterol synthesis (82) showed ‘ki’ of
1.9 m.mol/kg.In reducing urethral pressure invivo in dog.
More recently B.M. Khadikar et al.343  prepared 1,4-dihydro pyridine
derivatives (83) and tested its biological activity.
Out of many 1,4-dihydro pyridine  drugs only Flordipine (84) is N-substi-
tuted derivative that has proved to be very good calcium channel antagonist ,
contrary to be belief proposed by D.J.Triggle 344  that N-substituted 1,4-dihydro
pyridine was not shown good antihypertensive activity , probably the concept of that time




















                     (83)                                                                                         (84)
          R1=Methyl/Ethyl, R2=Methyl/Ethyl
          R=Alkyl/Aryl
N-methyl nimodipine (85) was found to possess antidepressive 345  char-
acteristics (20 mg.P.O reduce the immobile phase by approximately 22% com-
parison to control values), which provides excellent example of mechanism of















                                     (85)                                                                 (86)
V. Michael et.al.346  prepared antihypertensive and coronary vasodila-
tor N-substituted 1,4-dihydro pyridine(86).
Adam Daich et. al.347  prepared calcium antagonist effect of 1,4-dihydro
pyridine (87) and Margarita Suarez et.al.348  prepared Calcium antagonist



















                    (87)   X=O, S, NR5                                                 (88)
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on 1,4 dihydro pyridines  for their various methods of synthesis
and different biological activities, synthesis of 1 ,4 dihydro pyridines  have been
under taken which can be summarized in the following sections as under.




















PREPARATION  AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-
DIMETHYL-3,5-DICARBETHOXY-4-[1’-N-PHENYL-3’-(4”-METHOXY PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES .
In view of various biodynamic activit ies 326-341,  other properties
342-348 , and in order to have potent therapeutic agents, synthesis of 1-N-
aryl-2,6-dimethyl-3,5-dicarbethoxy-4-[1’-N-phenyl-3’-(4”-methoxy phenyl)-
pyrazol-4’-yl]-1,4-dihydro pyridines (XVIIa-j) have been under taken by the
cyclocondensation of different aromatic amines  with two moles of ethyl aceto
acetate  and 3-(p-methoxy phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde  in
ethanol.
The constitution of the products (XVIIa-j) have been delineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (XVIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized










(XVIIa-j)                 R=Aryl
S t u d i e s  o n  1 ,4-dihydro pyridines
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
251
IR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-4-[1’-N-
PHENYL-3’-(4”-METHOXY PHENYL)-PYRAZOL-4’-YL]-3,5-DICARBETHOXY-
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PMR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-3,5-
DICARBETHOXY-4-[1’-N-PHENYL-3’-(4”-METHOXY PHENYL)-PYRAZOL-4’-





































































































































































































































































































































































































































































      (XVIIa-j) R = Aryl




PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-
DIMETHYL-3,5-DICARBETHOXY- 4-[1’-N-PHENYL-3’-(4”-METHOXY PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES.
(A) Preparation of 1-N-(p-methyl phenyl)-2,6-dimethyl-3,5-dicarbethoxy-4-
[1’-N-phenyl-3’-(4”-methoxy phenyl)-pyrazol-4’-yl]-1,4-dihydro -
pyridine (XVIIg).
A mixture of 3-(p-methoxy phenyl)-1-N-phenyl-pyrazol-4-
carboxaldehyde  (2.78gm, 0.01 M), ethyl aceto acetate (2.60 ml, 0.02 M) and
p-toludine (1.07  gm, 0.01 M) in ethanol (30 ml) was heated under refluxed
condition for six hrs. The content was poured into ice cold  water. The
separated solid was filtered and crystallized from DMF:methanol (2:1). Yield
: 71%, M.P. : 126°C, R f1
 : 0.50,R f2
 : 0.72 (Required : C, 73.08%; H, 6.30%; N,
7.11% for C 36H37N3O5, Found : C, 73.01%; H, 6.24%;  N, 7.07%).
Similarly, other compounds (XVIIa-j) were synthesized. The physical data
are recorded in Table No. 17.
(B) Antimicrobial activity of 1-N-aryl-2,6-dimethyl-3,5-dicarbethoxy-4-
[1’-N-phenyl-3’-(4”-methoxy phenyl)-pyrazol-4’-yl]-1,4-dihydro-
pyridines (XVIIa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 17a, 17b & 17c.









































































   
























































































































































































































































































































































































   












   









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PREPARATION  AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-
DIMETHYL-3,5-DICARBMETHOXY-4-[1’-N-PHENYL-3’-(4”-METHOXY PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES .
In view of various biodynamic activities326-341 ,  other properties 342-348 ,
and in order to have potent therapeutic agents, synthesis of 1-N-aryl-2,6-
dimethyl-3,5-dicarbmethoxy-4-[1’-N-phenyl-3’-(4”-methoxy phenyl)-
pyrazol-4’-yl]-1,4-dihydro pyridines (XVIIIa-j) have been under taken by the
cyclocondensation of different aromatic amines  with two moles of methyl aceto
acetate  and  3-(p-methoxy phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde
in ethanol.
The constitution of the products (XVIIIa-j) have been delineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (XVIIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized










(XVIIIa-j)                 R=Aryl
S t u d i e s  o n  1 ,4-dihydro pyridines
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263
IR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-4-[1’-N-
PHENYL-3’-(4”-METHOXY PHENYL)-PYRAZOL-4’-YL]-3,5-DICARBMETHOXY-



































































































S t u d i e s  o n  1 ,4-dihydro pyridines
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
264
PMR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-3,5-
DICARBMETHOXY-4-(1’-N-PHENYL-3’-(4”-METHOXY PHENYL)-PYRAZOL-







































































































































































































































































































































































































































































































      (XVIIIa-j) R = Aryl




PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-
DIMETHYL-3,5-DICARBMETHOXY-4-[1’-N-PHENYL-3’-(4”-METHOXY PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES.
(A) Preparation of 1-N-(p-methyl phenyl)-2,6-dimethyl-3,5-dicarbmethoxy-
4-[1’-N-phenyl-3’-(4”-methoxy phenyl)-pyrazol-4’-yl]-1,4-dihydro-
pyridine (XVIIIg).
A mixture of 3-(p-methoxy phenyl)-1-N-phenyl-pyrazol-4-
carboxaldehyde  (2.78gm, 0.01 M), methyl aceto acetate (2.32 ml, 0.02 M)
and p-toludine (1.07  gm, 0.01 M) in ethanol (30 ml) was heated under re-
fluxed condition for six hrs. The content was poured into ice cold  water. The
separated solid was filtered and crystallized from DMF:methanol (2:1).  Yield  :
62%, M.P. : 159°C, R f1
 : 0.64,R f2
 : 0.48 (Required : C, 72.45%; H, 5.90%; N,
7.46% for C 34H33N3O5, Found : C, 72.39%; H, 5.84%;  N, 7.42%).
Similarly, other compounds (XVIIIa-j) were synthesized. The physical data
are recorded in Table No. 18.
(B) Antimicrobial activity of 1-N-aryl-2,6-dimethyl-3,5-dicarbmethoxy-
4-[1’-N-phenyl-3’-(4”-methoxy phenyl)-pyrazol-4’-yl]-1,4-dihydro-
pyridines (XVIIIa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 18a, 18b & 18c.
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PREPARATION   AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIM-
ETHYL-3,5-DICARBETHOXY- 4-[1’-N-PHENYL-3’-(4”-NITRO PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES.
In view of various biodynamic activities326-341 ,  other properties342-348
and in order to have potent therapeutic agents, synthesis of 1-N-aryl-2,6-
dimethyl-3,5-dicarbethoxy-4-[1’-N-phenyl-3’-(4”-nitro phenyl)-pyrazol-4’-
yl]-1,4-dihydro pyridines  (XIX a-j )  have been under taken by the
cyclocondensation of different aromatic amines  with two moles of ethyl aceto
acetate and  3-(p-nitro phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde i n
ethanol.
The constitution of the products (XIX a-j ) have been delineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (XIXa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized









(XIXa-j)                 R=Aryl
S t u d i e s  o n  1 ,4-dihydro pyridines
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IR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-4-[1’-
N-PHENYL-3’-(4”-NITRO PHENYL)-PYRAZOL-4’-YL]-3,5-DICARBETHOXY-


































































































S t u d i e s  o n  1 ,4-dihydro pyridines
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PMR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-4-[1’-
N-PHENYL-3’-(4”-NITRO PHENYL)-PYRAZOL-4’-YL]-3,5-DICARBETHOXY-






















































































































































































































































































































































































































































































































      (XIXa-j) R = Aryl




PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-
DIMETHYL-3,5-DICARBETHOXY-4-[1’-N-PHENYL-3’-(4”-NITRO PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES.
(A) Preparation of 1-N-(p-methyl phenyl)-2,6-dimethyl-3,5-dicarbethoxy-4-
[1’-N-phenyl-3’-(4”-nitro phenyl)-pyrazol-4’-yl]-1,4-dihydro pyridine (XIXg).
A mixture of 3-(p-nitro phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde
(2.93gm, 0.01 M), ethyl aceto acetate (2.60 ml, 0.02 M) and p-toludine (1.07
gm, 0.01 M) in ethanol (30 ml) was heated under refluxed condition for six hrs.
The content was poured into ice cold  water. The separated solid was filtered
and crystallized from DMF:methanol (2:1). Yield  : 70%, M.P. : 187°C, Rf1
 :
0.59,R f2
 : 0.59 (Required : C, 69.29%; H, 5.65%; N, 9.24% for C 35H34N4O6,
Found : C, 69.25%; H, 5.60%;  N, 9.18%).
Similarly, other compounds (XIXa-j) were synthesized. The physical data
are recorded in Table No. 19.
(B) Antimicrobial activity of 1-N-aryl-2,6-dimethyl-3,5-dicarbethoxy-4-[1’-
N-phenyl-3’-(4”-nitro phenyl)-pyrazol-4’-yl]-1,4-dihydro pyridines
(XIXa-j) .
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 19a, 19b & 19c.
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PREPARATION  AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-
DIMETHYL-3,5-DICARBMETHOXY-4-[1’-N-PHENYL-3’-(4”-NITRO PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES .
In view of various biodynamic activities326-341 ,  other properties342-348
and in order to have potent therapeutic agents, synthesis of 1-N-aryl-2,6-
dimethyl-3,5-dicarbmethoxy-4-[1’-N-phenyl-3’-(4”-nitro phenyl)-pyrazol-4’-yl]-
1,4-dihydro pyridines (XXa-j) have been under taken by the cyclocondensation
of different aromatic amines  with two moles of methyl aceto acetate  and  3-
(p-nitro phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde  in ethanol.
The constitut ion of the products  (X Xa- j)  have been del ineated by
elemental analyses, IR, PMR  and Mass spectral data.
The products (XXa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized









(XXa-j)                 R=Aryl
S t u d i e s  o n  1 ,4-dihydro pyridines
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IR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-4-[1’-
N-PHENYL-3’-(4”-NITRO PHENYL)-PYRAZOL-4’-YL]-3,5-DICARBMETHOXY-



































































































S t u d i e s  o n  1 ,4-dihydro pyridines
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PMR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-3,5-
DICARBMETHOXY-4-(1’-N-PHENYL-3’-(4”-NITRO PHENYL)-PYRAZOL-4’-









































































































































































































































































































































































































































































































































      (XXa-j) R = Aryl




PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIM-
ETHYL-3,5-DICARBMETHOXY-4-[1’-N-PHENYL-3’-(4”-N ITRO PHENYL)-
PYRAZOL-4’-YL]-1,4-DIHYDRO PYRIDINES.
(A) Preparation of 1-N-(p-methyl phenyl)-2,6-dimethyl-3,5-dicarbmethoxy-
4-[1’-N-phenyl-3’-(4”-nitro phenyl)-pyrazol-4’-yl]-1,4-dihydro -
pyridine (XXg).
A mixture of 3-(p-nitro phenyl)-1-N-phenyl-pyrazol-4-carboxaldehyde
(2.93 gm, 0.01 M), methyl aceto acetate (2.32 ml, 0.02 M) and p-toludine
(1.07  gm, 0.01 M) in ethanol (30 ml) was heated under refluxed condition for
six hrs. The content was poured into ice cold  water. The separated solid was
filtered and crystallized from DMF:methanol (2:1). Yield  : 48%, M.P. : 112°C,
Rf 1
 :  0.48,Rf 2
 :  0.58 (Required :  C, 68.50%; H, 5.23%; N, 9.69% for
C33H30N4O6, Found : C, 68.44%; H, 5.18%;  N, 9.63%).
Similarly, other compounds (XXa-j) were synthesized. The physical data
are recorded in Table No. 20.
(B) Antimicrobial activity of 1-N-aryl-2,6-dimethyl-3,5-dicarbmethoxy-4-[1’-
N-phenyl-3’-(4”-nitro phenyl)-pyrazol-4’-yl]-1,4-dihydro pyridines (XXa-j).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 43. The MIC values of test solution are recorded in Table
No. 20a, 20b & 20c.
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